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     The goal of this research was to determine safety, tolerability and pharmacokinetics of 
2ME2 in patients with solid tumors and determine maximum tolerated dose (MTD).  The 
following hypotheses were tested: 1) 2ME2 will be well tolerated in clinic when given 
orally and will have quantifiable effects on the ex vivo markers of angiogenesis and 
 xxi
apoptosis;  2) 2ME2 will exhibit linear pharmacokinetics;  3) Plasma protein binding will 
be extensive and linear; 4) Sulfation will be the major metabolic pathway for 2ME2. 
     This was a phase I dose escalation study.  Twenty patients with refractory solid tumors 
were enrolled.  2ME2 was administered orally starting at 400 mg bid with dose escalation 
up to 3000 mg bid.  Pharmacokinetic sampling was done up to 50 hours after single oral 
dose for characterization of pharmacokinetics and plasma drug concentrations which 
were determined by liquid chromatography tandem mass-spectrometry [LC/MS/MS, 
LOQ: 1ng/mL].  Circulating plasma concentrations were very low at all dose levels with 
high interindividual pharmacokinetic variability.  Median plasma half-life was about 1-2 
days.  The unphysiologically high oral CL/F and Vd/F values reflect low oral 
bioavailability of 2ME2.  There was no dose proportional increase in Cmax or AUClast.  
There were no dose limiting toxicities at highest dose level, therefore MTD was not 
defined.  The clinical trial was closed due to the extremely low plasma concentrations of 
2ME2 achieved. 
     Hepatic in vitro metabolism studies showed that 2ME2 was metabolized by CYP 450 
enzymes (CYP 1A1, 1A2, 3A4, 3A5 and 2E1) to four major metabolites.  Hepatic phase 
II metabolism studies revealed two major glucuronide metabolites of 2ME2.  Sulfation 
did not play a major role in metabolism of 2ME2.  Total in-vivo hepatic clearance was 
estimated as 862 mL/min, primarily due to glucuronidation.  Less than 0.01 % of total 
administered dose of 2ME2 was excreted unchanged in urine, and only about 1% was 
excreted as glucuronides. 
     Plasma protein binding of 2ME2 was studied using equilibrium dialysis.  Mean 
unbound fraction of 2ME2 (fu) in plasma of patients and healthy human volunteers was 
  
 xxii
0.019 ± 0.0043 and 0.027 ± 0.0019 respectively.  Binding was concentration-independent 
and unaffected by presence of 2-methoxyestrone.  2ME2 binds to albumin, α1-acid 
glycoprotein (AAG) and sex-hormone binding globulin (SHBG).   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER ONE 
 
Introduction 
 
 
 
Estrogen Biosynthesis 
The endogenous sources of estrogens are the ovary and the adrenal glands in the 
female during pre-menopausal, non-pregnant life. During the post-menstrual period, the 
major sources of estrogen are adipose tissue and the skin 1. Androgens (C19 steroids) are 
the common chemical precursors of estrogens (C18 steroids); 17β-hydroxysteroid 
dehydrogenase (17β-HSD) converts androstenedione to testosterone, which in turn is 
rapidly converted to estradiol (E2) by demethylation at the C19 position followed by 
aromatization, which can be catalyzed by both aromatase (CYP19) and 17β-HSD 2. Other 
than estradiol, the ovary also secretes estrone (E1), which serves as an alternative source 
for estradiol; 17β-HSD type 1 primarily catalyzes the reduction of estrone to estradiol 3, 
whereas 17β-HSD type 2 primarily catalyzes the reverse metabolic transformation 3.  In 
case of males, the Leydig cells and germ cells of the testes produce estrogen 4.    
The other pathway which plays an important role in estrogen biosynthesis is the 
peripheral conversion of C19 precursors in adipose tissue to free estrogens in obese 
women and men 5,6. This is the predominant pathway of estrogen biosynthesis in post-
menopausal life. Although these extragonadal tissues have the capacity to convert C19 
steroids to C18 steroids, unlike the ovaries, they lack the ability to synthesize C19 
precursors. Hence, estrogen production in the extragonadal sites is totally dependent on 
 2
circulating C19 precursors 1. Estriol (E3) is a peripheral metabolite of estradiol and 
estrone, and is considered a detoxification (or inactivation) product since it is less active 
than estrogen. Oral contraceptive pills and estrogen replacement therapy are exogenous 
sources of estrogens.      
 
Estrogen Metabolism 
Phase I Metabolism  
     The metabolism of endogenous estradiol primarily involves cytochrome P450 (CYP)-
dependent hydroxylations at positions C2, C4, or C16, yielding either 2-hydroxy- or 4-
hydroxyestradiol, or 16α-hydroxyestradiol, respectively. The 2-hydroxylation of estradiol 
and estrone, catalyzed by the CYP1A1/2 and CYP3A isozymes 7-9, is the major metabolic 
pathway in the liver as compared to the 4-hydroxylation, which is exclusively catalyzed 
by CYP3A 10.  In humans, as much as 50% of estrogen is hydroxylated at the C2 position, 
with men exhibiting less extensive metabolism at this position than women 11.  The 2-
hydroxyl metabolites of estradiol and estrone are further metabolized by a catechol-o-
methyl transferase (COMT), which converts these products to 2-methoxyestradiol (2-
ME2) and 2-methoxyestrone, respectively.  COMT is found in many tissues including the 
uterus, liver, kidney, breast, lymphocytes and erythrocytes 12,13. 
4-Hydroxyestradiol has been associated with renal cancer in Syrian male hamsters 
14. This metabolite also undergoes metabolic redox cycling to generate free radicals such 
as superoxides and chemically-reactive (semi-)quinone estrogen intermediates, which 
may damage DNA and other cellular components, induce cell transformation and initiate 
tumorigenesis 15,16. The (semi-) quinones can also form conjugates with glutathione, the 
  
 3
formation of which is catalyzed by glutathione S-transferase (GST), or they can be 
reduced to catechol estrogens by quinone reductases. DNA adducts can result from these 
reactive metabolites if the inactivating conjugative pathways are incomplete or absent. 
Quinone metabolites formed during redox cycling bind covalently to DNA, and may 
produce several forms of DNA damage, including single-strand breaks and/or 
hydroxylation of guanine bases of DNA 15.  
The role of 16α-hydroxyestradiol in carcinogenesis has not been clearly 
established. This metabolite is produced in abundance during pregnancy, and women 
who have been pregnant have a reduced risk of breast cancer. Two epidemiologic studies 
suggested that the 16α-hydroxylation of estradiol was more pronounced in women with 
breast cancer 17 and in women with a high familial risk of breast cancer 18, than in 
controls. However, a third study found no elevation of the 16α-hydroxylation pathway in 
patients with breast cancer as compared to controls 19. 
 
Phase II metabolism 
 The phase II metabolism of estrogens involves sulfation, glucuronidation, 
glutathione conjugation, and o-methylation.  Sulfation of steroids is an important 
biotransformation step involved in the regulation of tissue specific estrogen levels. All of 
the hydroxylated metabolites produced by phase I reactions can undergo sulfation via the 
estrogen sulfotransferase (SULT) isoform 1A1, a cytosolic enzyme that also conjugates 
estradiol and estrone. Estrone sulfatase, a membrane bound enzyme, is responsible for the 
desulfation of estrone sulfate and exhibits its highest activity in the liver 20. The sulfated 
forms of many steroid hormones exhibit half-lives up to ten-fold longer than the 
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desulfated form in plasma. Biological "cycling" of sulfated/desulfated steroid hormones 
has been demonstrated. The intracellular sulfated moiety represents a readily accessible, 
yet biologically inactive, storage form for many steroid hormones whereby desulfation 
regenerates the biologically active steroid.  The transport of estrone sulfate into steroid 
hormone responsive cells is not well understood; however some studies have shown that 
a human organic anion transporter (Oatp1) has high affinity for both sulfate and 
glucuronide estrogen conjugates 21.  SULT 1E1 catalyzes the sulfation of 17β-estradiol 
and SULT1A1 catalyzes the sulfation of 2ME2 22, while SULT2B1 is known to catalyze 
the sulfation of dihydroxy-epi-androsterone. An enzyme known as steroid sulfatase is 
involved in the desulfation of various conjugated products, including sulfate conjugates 
of estrone, 17β-estradiol, and dihydroxy-epi-androsterone. 
Glucuronidation by uridine-5’-diphosphate glucuronosyltransferase (UGT) of 
estrogens is generally accepted to play a principal role in elimination pathways followed 
by excretion of the conjugates through urine and feces. In a study comparing UGT 
activity in matched breast ductal carcinoma and peritumoral tissues, activity was reported 
in tissues from only 4 out of 12 individuals studied 23. Furthermore, in those 4 paired 
samples, the level of activity was 5-fold lower in the tumor tissue than in the peritumoral 
tissue, suggesting that glucuronidation does play an important role in detoxification of 
estrogens. 
Results of previous studies indicate that the UGT1A1, UGT1A3, and UGT2B 
family of isoenzymes catalyze catechol estrogen glucuronidation 24,25. When the 
glucuronidation kinetics of expressed human UGTs with catechol estrogens was 
investigated, it was found that UGT2B6(Y) reacted with a higher efficiency toward 4-
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hydroxyestrogen catechols, whereas UGT1A1 and UGT1A3 showed higher activities 
toward 2-hydroxyestrogens 26. It has also been shown that enzymatic de-conjugation of 
estrogen glucuronides occurs by β-glucuronidases, and that it may be an important source 
of both primary estrogens and their catechol metabolites in preclinical models 27.   
COMT catalyzes the o-methylation of catechol estrogens 14,28-30 by transferring a 
methyl group from the co-factor S-adenosyl methionine to the 2-hydroxyl or 4-hydroxyl 
groups, and forms 2-ME2 and 4-methoxyestradiol 31. This enzyme is found in many 
tissues including the uterus, liver, kidney, breast, lymphocytes and erythrocytes 12,13. 
Another important function of COMT is the o-methylation and inactivation of 
endogenous catecholamines and catechol drugs such as levodopa and methyldopa.32,33 It 
has been shown that o-methylation of 2-hydroxyestradiol by COMT is protective against 
its oxidative DNA damage in MCF-7 cells in vitro 34. Figure 1 provides an overview of 
the various metabolic routes of estrogens (modified from 35) and Figure 2 depicts the 
chemical structure of 2-methoxyestradiol (2ME2). 
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Figure 1:  Estrogen Biotransformation Scheme 
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Figure 2:  Chemical Structure of 2-methoxyestradiol 
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Endogenous 2ME2 production: 
     2-Methoxyestradiol (2ME2) is synthesized in vivo by hydroxylation at the 2-position 
of estradiol, and subsequent catechol-O-methyltransferase mediated O-methylation.    
Endogenous plasma concentrations of 2ME2 are in the picomolar range under normal 
physiological conditions; however, during late pregnancy the values can increase more 
than 1000-fold 36.  Table 1 provides a detailed synopsis of the levels of 2-
methoxyestradiols in humans in various physiological conditions (adapted from 37). 
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Table 1: Endogenous concentrations of 2-methoxyestrogens in human serum in 
various physiological conditions: 
 
 
                        Median                  Range           N 
 
                       (pg/mL)      (pg/mL)       
    
 
Men  
 
19-58 years  <10.3  <10.3-35.5         22 
 
 
Women 
 
Follicular phase             46                        18-63                             8                
 
Luteal Phase                  70                       31-138                            8 
 
Postmenopausal   10        21-76                      10 
 
 
Pregnant 
 
11-16th week    674                     216-1,678           46 
 
 
37th-40th week  3,768       2,035-10,691           34 
 
 
In labor  3,580       1,353-9,974            41 
 
 
Newborn 
 
Cord serum  1,608        575-3,095             41 
 
  
a Abbreviations: N, total number of replicate observations  
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Mechanisms of antitumor action of 2ME2 
     The antitumor activity of 2ME2 is thought to be due to the following components:     
1) antiproliferative and antimetastatic activity ; 2) anti-angiogenic activity. 
 
Antiproliferative & Antimetastatic Activity:   
     2ME2 inhibits the growth of pancreatic cancer cell lines (PaTu 8902, 8988t and 
8988s) by 50-90% in a dose- and time-dependent fashion 38.    Also, studies in an in vivo 
murine lung metastasis model, showed that 2ME2 inhibited the number of lung colonies 
by 60% as compared with controls 38.   
     Xenograft experiments found that 2ME2 targets both the tumor and the tumor 
vasculature.  Oral administration of 2ME2 was effective at reducing the rate of xenograft 
tumor growth and tumor vascularization in mice in the absence of significant toxicity.  
After 2 weeks of treatment with 100 mg/kg/day, the tumor growth of MethA sarcoma and 
B16 melanoma cells was inhibited by 66% and 88%, respectively 39.  A concomitant 
reduction in tumor vascularization was also observed 39.  Also, interesting is the fact that 
the antitumor activity is not estrogen receptor dependent 40.   The estrogen receptor (ER) 
negative human breast cancer line, MDA-MB-435 was found to be sensitive to 2ME2 
treatment.  Binding studies using recombinant proteins showed that 2ME2 has a Ki of 21 
nM for ERα and a Ki of 417 nM for ERβ.  E2 has Ki of 0.042 nM for ERα and a Ki of 0.132 
nM for ERβ. Thus, 2ME2 has 500- and 3200-fold lower affinity than E2 for ERα and ERβ 
respectively, and the antiproliferative activities of 2ME2 do not require ERs and are not 
influenced by ER antagonists or agonists 41.  Table 2 shows a comprehensive list of the 
cell lines that are inhibited by 2ME2: 
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Table 2:  Cell lines inhibited by 2ME2 
Cell Type    Inhibitory Concentrations        References 
    (µM)  (µg/mL) 
_______________________________________________________________________ 
Human Tumor 
Lung (HOP-62)  0.7  0.21                               42 
Lung (H460)   5.0  1.51                                             43 
Lung (A549)   5.0  1.51                                             43 
Colon (HCT-116)  0.47            0.14                                              43                                          
CNS (SH-SY5Y)  1.3            0.39                              42 
CNS (SF-539)   0.32            0.10                              42 
Melanoma (UACC-62) 0.36            0.11                              42 
Ovarian (OVCAR-3)  0.21            0.06                              42 
Renal (SN12-C)  0.95           0.29                              42                     
Prostate (DU-145)  1.8           0.54                              42 
Breast (MDA-MB-435) 0.08-0.6         0.02-0.18                                    40, 44 
Breast (MDA 231)  1.03         0.31                              44 
Breast (MCF-7)  0.45         0.14                   44 
Lymphoblast (Jurkat)  0.3         0.09                   45 
Lymphoblast (TK6)  1-2         0.3-0.6                    46 
Lymphoblast (WTK1) 1-2         0.3-0.6                   46 
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Human Non Tumor 
Skin Fibroblast (HFK2)      2.0  0.6                                              39 
 
Human Endothelial 
HUVEC        0.45 0.14                                              44 
Non-Human-Tumor 
Lung (Lewis Lung-Murine)       1.68 0.51                                               44 
Melanoma (B16BL6-Murine)      0.4  0.12                                    44          
Melanoma (B16F10-Murine)       0.3  0.09                                               44 
Endothelial (EOMA-Murine)      0.89            0.27                         44           
Endothelial(H5V-Murine)      1.0  0.30                                                          47      
Non-Human Non Tumor 
Lung (V79-Hamster)       3  0.91                                                          48 
Ovarian (Granulosa-Porcine)      3  0.91                                               49 
Smooth Muscle (Aorta-Rabbit)  1  0.3                                                          50 
Adipocytes (Murine)      1.7  0.51                                               51 
Non-Human Endothelial 
Brain Capillary (Bovine)    0.19-0.49 0.06-0.15                                  40 
Pulmonary artery (Bovine)      0.5  0.15                                              52 
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Anti-Angiogenic Activity:          
     Angiogenesis has been shown to be a critical step in the proliferation of cancers with 
size > 1 mm3 53,54.  2ME2 reduces tumor vasculature in mice injected subcutaneously 
with Meth A sarcoma and B16 melanoma cells and treated orally with 2ME2 39, 40.  In 
vivo antiangiogenic activity of 2ME2 has been demonstrated in the corneal micropocket 
40 and chick chorioallantoic model (CAM) systems 52. In the corneal micropocket VEGF 
and bFGF induced neovascularization was reduced by 54% and 39%, respectively.  In the 
CAM model, 2µM of 2ME2 exposure for 3 days completely prevented bFGF-induced 
angiogenesis.  In vitro 2ME2 has been found to inhibit the neovascularization developing 
from the rat aortic ring assay 55, 56.  2ME2 appears to affect the angiogenesis cascade at 
various steps.   It also blocks the tubule formation as well as the invasion through the 
collagen matrix 57.     
     No difference in the number of micro-vessels (CD 31 staining) within MIA PaCa 
(Pancreatic Cancer) pulmonary metastases was noted in those animals treated with 
1mg/day of 2ME2 versus control 38.  Hence, ambiguity exists as regards to the exact 
mechanism of antiangiogenic properties of 2ME2.   Although, 2ME2 has been labeled as 
an anti-angiogenic agent, endothelial cells are not necessarily more sensitive to its anti-
proliferative effects.  The anti-angiogenic and apoptotic activity of 2ME2 varies with cell 
type and the regulatory microenvironment 36.  For some murine tumor models 
administration of oral 2ME2 reduces the rate of tumor growth without signs of toxicity 
with a concomitant reduction in tumor vascularization 39.  Thus, there is sufficient data to 
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establish that 2ME2 effectively inhibits angiogenesis, but it is still difficult to isolate the 
exact mechanism of action.   
 
Mechanisms of Action of 2ME2: 
     The above-mentioned antitumor activities of 2ME2 result from the following 
mechanisms of action: 1) Apoptotic Activity; 2) Microtubule Activity; 3) Production of 
superoxides 
 
  Apoptotic Activity 
     2ME2 appears to induce Caspase-3 activation and causes apoptosis in gastric 
carcinoma cell lines (SC-M1 and NUGC-3) through the caspase activation cascade 
resulting in G2/M arrest 46. When gastric carcinoma cell lines were treated with 2ME2 for 
24 hours, it resulted in a reduction of cell viability in a dose- dependent and a time-
dependent fashion.  Moreover, the caspase cascade induced by 2ME2, which is believed 
to be the major mechanism causing apoptosis, begins with the activation of caspase-8 
followed by caspase-3 and eventually induces DNA fragmentation.  2ME2 induced 
apoptosis requires caspase activation and the sequential activation of caspase 8, 9 and 3 is 
consistent with the triggering of apoptosis through the membrane bound receptor 58.  
Flow cytometry established 2ME2 induced G2/M cell cycle arrest.    
     In some studies the amount of apoptosis detected was correlated with the 
antiproliferative activity of 2ME2.  Apoptotic cell death induced by 2ME2 has been 
shown to be p53 mediated 43.  Increased activity of functional p53 has been observed 
after treatment with 2ME2.  The number of metastatic lung colonies has been found to 
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synergistically reduced in mice treated with 2ME2 (50 mg/kg/day) in combination with 
adenoviral p53 59.  On the other hand, there are several other reports indicating that the 
induction of apoptosis by 2ME2 may be p53-independent 38, 60.  2ME2 treatment results 
in upregulation of death receptor 5 (DR5) expression both in vitro and in vivo 58.  
Moreover, blocking death receptor signaling by expression of dominant-negative FADD 
severely attenuates the ability of 2ME2 to induce apoptosis.    
 
Microtubule Activity 
     A clear increase in the mitotic figures has been demonstrated in cells treated with 
2ME2 during the metaphase 45, 48.  In endothelial cells, 2ME2 caused selective disruption 
of microtubules as opposed to other cytoskeletal structures 60.  Also, micromolar 
concentrations caused disruption of microtubular network in non-synchronized Chinese 
hamster V79 cells 48 and multipolar and irregular spindles in synchronized MCF-7 cells.  
On the contrary, 2ME2 has been found to inhibit aromatase activity, which is a 
characteristic observed with drugs that stabilize tubulin and not with agents that inhibit 
tubulin polymerization 61.     
     2ME2, in superstoichiometric concentrations, inhibits the nucleation and propagation 
of phases of tubulin assembly, but does not affect the reaction extent 62.  Similarly, in 
substoichiometric concentrations, 2ME2 completely inhibits polymerization.  2ME2 
inhibits the rate but not the degree, of polymerization and depolymerization of tubulin 
induced by other agents.  The inhibition of colchicines binding to tubulin was found to be 
competitive in nature (Ki of 22 µM).  Thus, it is speculated that 2ME2 binds to the 
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colchicine site of tubulin, and depending on the reaction conditions, either inhibits 
assembly or seems to be incorporated into a polymer with altered stability properties 62. 
 
Production of Superoxides 
     There have been two contradictory reports over this subject matter.  Huang et al 63 
have reported that 2ME2 and 2-hydroxyestradiol inhibit both Cu-, Zn- and Mn-
superoxide dismutases and are toxic to human leukemia cells.  Kachadourian et al 64 
showed that, when human leukemia HL-60 cells were incubated in a medium containing 
2ME2, cells showed 53% decrease in aconitase activity (aconitases are very sensitive to 
superoxide mediated inactivation) as compared to controls. Paraquat (superoxide 
generating redox cycling agent) decreased aconitase activity in HL-60 cells by 67%.  
Kachadourian et al showed that, although 2ME2 supports the increased production of 
superoxides, it does not produce that effect by inhibiting superoxide dismutase.   
 
Cardioprotective effects: 
     It has been suggested for years that estradiol may protect premenopausal women 
against coronary artery disease 60.  Recent studies hint at the possibility of these 
cardioprotective effects being independent of the estrogen receptor status 65, 66. 2-
hydroxyestradiol (2-OHE2) and 2ME2 are two metabolites of estrogen, which possess 
little or no affinity for ERs.  Recent studies also indicate that these two metabolites, 2-
OHE2 and 2ME2, are more potent than estradiol in preventing vascular smooth muscle 
cell (VSMC) growth 3.   
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     When the local metabolism of estradiol to methoxyestradiols was tested in human 
vascular smooth muscle cells (VSMCs) 67 it was reported that methoxyestradiols and 
their precursors, hydroxyestradiols, are 1) more potent than estradiol in inhibiting VSMC 
growth  2) the inhibitory effects of estradiol on VSMC growth are enhanced by CYP450 
inducers; and 3) the inhibitory effects of estradiol, both in presence and absence of 
CYP450 inducers, are abolished by CYP450 and COMT inhibitors.   
 
Estrogenic Activity of 2ME2 
    2ME2 has 2000 fold lower affinity for the estrogen receptors (ER) than estradiol 38.  
When administered continuously at 1µg/hr to ovariectomized rats, 2ME2 was ineffective 
in sustaining uterine growth and failed to induce estrus in ovariectomized mice.  In 
contrast, 2-hydroxyestrone, 4-methoxyestrone and estradiol had a strong uterotropic 
activity 38.  With chronic administration, 2ME2 did not affect the seminal vesicle weights, 
while estradiol significantly reduced the seminal vesicle weights in male mice.  Similarly, 
no tumors were reported in male Syrian hamsters receiving long-term exposure to 2ME2 
as compared to estrogens, which caused the induction of renal tumors. 
     Estradiol, 4-hydroxyestradiol and 2-hydroxyestradiol were found to sustain tumor 
growth of an estrogen-dependent hamster kidney tumor cell line, H-301 cells 39.  Also, 
MCF-7, which is an estrogen dependent cell line, showed sustained proliferation of these 
cells at low concentration of estradiol (0.1nM) while concentrations up to 10 µM of 2ME2 
were not able to sustain the proliferation of these cells 68. 
    However, in toxicology studies, high doses of 2ME2 administered orally to rats daily 
for 14 and 28 days and dogs treated for 28 days showed estrogenic activity 68.   It is 
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speculated that this estrogenic activity may be due to the formation of                             
2-hydroxyestradiol and possibly from other not yet identified metabolites of 2ME2 
interacting with ER.   
 
Preclinical Pharmacokinetics of 2ME2 
 
    Preliminary pharmacokinetic studies with 2ME2 were carried out in male and female 
CD2F1 mice using oral, intravenous or subcutaneous administration of labeled              
[3H-2-ME2] and non-labeled compound.  Following oral administration of 100 mg/kg to 
male mice, Cmax of 190ng/mL was observed in plasma 12 minutes after dosing.  The drug 
concentrations in plasma fell below 50ng/mL within 1 hour and were undetectable after 2 
hours.  Similarly, in female mice, the pharmacokinetic profile of 2ME2 after oral 
administration demonstrated a rapid absorption and elimination pattern, although values 
for Cmax (35ng/ml) and tmax (30 minutes) were different from the values observed in 
males.  Following intravenous administration of 3mg/kg, the plasma concentrations were 
undetectable within 60 minutes for both the male and the female populations.  There was 
a sizeable difference in the half-lives estimated between the male (t1/2 = 285 min) and 
female (t1/2 = 114 min) populations.  Table 3 provides a summary of pharmacokinetic 
parameters from preclinical studies: 
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Table 3:  Summary of pharmacokinetic parameters after preclinical studies in mice: 
Oral 
(100 mg/kg) 
Intravenous 
(3mg/kg) 
Subcutaneous 
(20mg/kg) 
Parameters 
Male 
 
Female 
 
Male Female Male Female 
AUC (µM*min) 35.9 53.8 112 84 34.6 232 
Cmax (ng/ml) 190 35 >500 > 500 ND ND 
tmax (min) 12 30 ND ND ND ND 
t1/2 β (min) ND ND 285 114 ND ND 
CLtot (mL/min) ND ND 22 29 ND ND 
Foral (%) 0.9 1.9 ND ND ND ND 
 
Abbreviations: ND, not determined 
 
 
     Total radioactivity levels could be measured up to 60 hours post administration of 
oral, intravenous and subcutaneous doses and the concentrations were at least 10- to 100-
fold higher than the parent compound.  Thus, suggesting that 2ME2 gets metabolized 
extensively, and the metabolites are detectable in plasma for a long period of time. 
 
 
 Metabolism (in vitro studies) 
 
     The in vitro metabolism of 2ME2 by pooled male and female liver microsomes of rats, 
mice, dogs and humans was investigated, it was found that the normalized half life in 
mice, rats and humans was less than 10 minutes.  The half-life in case of dogs was found 
to be 29 minutes.  2-methoxyestrone (2-ME1) was identified as a major metabolite of 
human and mouse liver microsomes.  The other metabolites identified in human liver 
microsomes were 2-hydroxyestradiol (2-OHE2) and 2-hydroxyestrone (2-OHE1).  When 
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2ME2 was incubated with cDNA-expressed cytochrome P450s (CYP 1A1, 1A2, 2A6, 
2B6, 2C9, 2C19, 2D6, 2E1 and 3A4) with NADPH generating system, significant 
metabolism was observed with CYP1A2 (91% degradation), followed by CYP3A4 
(35%), CYP2C9 (33%) and CYP2E1 (31%).   
     Glucuronidation of 2ME2 has been observed in UDPG-acid fortified mouse and 
human microsomal preparation preparations.  Evidence of polar conjugates has been 
observed in vivo in murine urine after 2ME2 administration.  
  
Plasma protein binding (in vitro studies) 
     In vitro plasma protein binding of 2ME2 evaluated by using murine and human 
plasma has been found to be more than 99% 68. 
 
In-vivo Excretion 
     Excretion studies in male and female CD2F1 mice given a single dose of radiolabeled 
[3H]-2-ME2 were performed and urine and feces were collected for 24 hours following 
administration.  The recovery of total radioactivity in case of males was 42% 
(urine=17%, feces=25%) and 54% in case of females (urine=29%, feces=25%).   
 
Pharmacokinetics of orally administered estrogens in humans 
     The most commonly prescribed estrogen component of Hormone Replacement 
Therapy (HRT) is Premarin® (Wyeth-Ayerst Laboratories, Canada) which is a mixture of 
ten biologically active conjugated equine estrogens 69.  Tables 4 and 5 depict the 
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pharmacokinetic parameters of estrone and 17 β-estradiol, two major estrogens in 
Premarin after a single oral dose of two tablets of 0.625 mg.   
 
 
 
Table 4 Total Estrone: 
Cmax (ng/mL)    4.01 ± 1.7 
tmax (h)     8.0 ± 2.3 
AUCt (ng*h/mL)   60.5 ± 24.8 
AUC∞ (ng*h/mL)   63.8 ± 26.8 
t1/2 (h)    14.8 ± 3.9 
 
Table 5 Total 17 β-estradiol: 
Cmax (ng/mL)    0.43 ± 0.2 
tmax (h)     10.3 ± 5.1 
AUCt (ng*h/mL)   6.0 ± 2.5 
AUC∞ (ng*h/mL)   6.4 ± 2.4 
t1/2 (h)    15.9 ± 5.8 
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Absorption 
     Estrogens are generally well absorbed orally 70.  Peak plasma concentration of 4 
ng/mL occurs approximately 8 hours after a dose of two 0.625 mg tablets of conjugated 
estrogens 69.  The bioavailability is poor because of significant first pass effect by 71, 
which begins with sulfation of estrogens in the gastrointestinal tract.  Estrogens are then 
metabolized to inactive compounds in the liver (sulfates and glucuronides) and excreted 
in the urine and bile.  Estradiol is excreted in the urine as the sulfate and glucuronide 
esters along with a small amount of unchanged drug.  
 
Distribution 
     Dunn et al72 have established that in human females 37 % of estradiol is SHBG bound, 
61% is albumin bound and 1.8% is free while in human males 78 % of estradiol is 
albumin bound, 20% is SHBG bound and 2.3% is free.  Estriol is not bound to plasma sex 
hormone-binding globulin (unlike estradiol or estrone) (Padwick 1986, Cardozo 1998). 
 
Metabolism and Excretion 
     Estradiol is rapidly metabolized in the liver to less active estriol and estrone.  It Orally 
administered estradiol is excreted in the urine as the sulfate and glucuronide esters along 
with a small amount of unchanged drug 70.   Circulating estrogens exist in a dynamic 
equilibrium of metabolic interconversions.  Estradiol is converted reversibly to estrone, 
and both can be converted to estriol, which is the major urinary metabolite.  Studies of 
quantification of biliary and urinary metabolites of exogenous estrogens in human 
  
 22
subjects with biliary drainage after the administration of intravenous E3 found that 79% 
of the glucuronide conjugate was excreted in urine and 81% of the sulfate conjugate was 
excreted in bile73.  Following the administration of intravenous estrone (E1) in humans 
with biliary drainage also biliary products appeared to be composed mostly of sulfate 
conjugates whereas the urinary products consisted mostly of glucuronidates74. 
 
Preliminary Clinical Results 
          There are numerous 2ME2 clinical trials underway in the U.S.  A clinical trial 
being conducted at Indiana University, Indianapolis, IN has reported no grade IV toxicity 
and only minor grade III toxicity which could be attributed to disease progression 75, 
following the administration of 200, 400, 600, 800 and 1000 mg/day to a total of 15 
patients. The half-life of the drug in plasma was reported to be 10 hours.  Some patients 
showed clinically significant reduction in bone pain and analgesic use while receiving 
2ME2.  All patients receiving 1000 mg (N=3) experienced hot flashes.    
     In a phase II multi-center randomized double blind trial of two doses (400 and 1200 
mg/day) of 2ME2 in patients (N=33) with hormone refractory prostate cancer, 2ME2 was 
very well tolerated and PSA stabilization and declines were observed 76.  In a small 
number of patients, grade 2 and 3 liver function abnormalities were observed which 
normalized rapidly after discontinuation of 2ME2.  Analysis of growth ex-vivo factor data 
indicates that there is an initial rise in the levels of plasma VEGF & bFGF from baseline 
to month 1, followed by decrease of 40% and 55% respectively from month 1 to month 3 
on study.   
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     A phase I study of 2ME2 plus docetaxel in patients with metastatic breast cancer 
(N=15) was performed at Indiana University 77.  Docetaxel at 35 mg/m2 was administered 
weekly for 4 of 6 weeks and 2ME2 was given orally (200-1000 mg/day) once daily for 28 
days followed by a 13-day observation period in cycle one, continuously thereafter.  
After a maximum of 6 cycles of combined therapy, responding or stable patients 
continued 2ME2 alone until progression.  There were no grade 4 toxicities.  Grade 3 
fatigue, diarrhea and hand-foot syndrome occurred in 5, 4 and 1 patients respectively.  3 
patients had grade 3 transaminase elevations that returned to normal with continued 
treatment.  2ME2 did not alter docetaxel clearance or dose-normalized AUC. Extensive 
metabolism to 2-methoxyestrone (2ME1) was observed.  2ME2 trough and peak levels 
were not altered by concurrent docetaxel administration.   
  
  
CHAPTER TWO 
 
Hypotheses and Objectives 
 
 
 
Overview 
 
     This study is a phase I clinical trial of a novel anticancer agent, 2-methoxyestradiol       
(2ME2), with the intent of determining the safety, tolerability and pharmacokinetic and 
pharmacodynamic profile, as well as in vitro metabolism and plasma protein binding of 
2ME2, in patients with solid tumors.  The hypotheses that will be tested and the 
objectives of the study are as follows: 
Hypotheses 
 
1. 2ME2 will be well tolerated in the clinic when given orally at the proposed doses 
and will have quantifiable effects on the ex vivo markers of angiogenesis and 
apoptosis in the tumor cells. 
2. 2ME2 will exhibit linear pharmacokinetics.  Single-dose pharmacokinetics will 
predict steady state pharmacokinetics. 
3. The plasma protein binding will be extensive and linear in the clinically 
achievable concentration range. 
4. Hepatic metabolism by sulfation will be the major metabolic pathway responsible 
for the metabolism of 2ME2.  
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Objectives 
 
1. To develop and validate an LC/MS/MS assay that will quantitate 2ME2 in human 
plasma, urine, β-glucuronidase and sulfatase treated urine; human liver 
microsomes as well as pooled human cytosol and validate it. 
2. To characterize the pharmacokinetics of oral 2ME2 in plasma and urine of 
patients with solid tumors. 
3. To perform pharmacodynamic correlations, if any, with the in-vivo and ex-vivo 
markers of biological effect and/toxicity. 
4. To assess the in vitro plasma protein binding of 2ME2. 
5. To characterize the in vitro metabolism of 2ME2 in humans. 
 
 
  
  
CHAPTER THREE 
 
Bioanalytical method for quantitating 2-methoxyestradiol                                           
in Human Plasma and Urine 
 
 
Introduction 
Various methods have been described for the quantitative determination of 2ME2 
in biological matrices.  A radioimmunoassay using an 125I-labelled ligand was described 
to quantify 2-methoxyestrogens in human serum 37, but is marred by cross-reactivity with 
similar estrogenic compounds, i.e., 2-methoxyestrone, 2-methoxyestriol and 2-
hydroxyestrone.  Chromatographic methods for 2ME2 include an HPLC/UV assay for 
extracts from the vitreous humor of rabbit eyes78, a GC/MS assay for rat plasma79 and an 
HPLC/UV method for human plasma80.  Because of problems related to poor specificity 
at or near lower limit of quantitation of these assays and the need for adequate sensitivity 
in view of the lower circulating concentrations of 2ME2 in plasma of patients treated 
with the drug, it was considered essential to improve currently available procedures.  
Hence, a simple, specific and rapid assay method was developed and validated for the 
determination of 2ME2 in human plasma and urine to characterize the clinical 
pharmacokinetics of 2ME2 was developed.  The method discussed in this chapter 
describes the development and validation of a novel, sensitive and specific analytical 
method for quantification of 2ME2 in human plasma based on liquid chromatography 
with atmospheric pressure chemical ionization (APCI)–tandem mass spectrometric 
detection.  
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Experimental 
Chemicals and reagents 
2ME2 (HPLC purity, 99.99%) was obtained from Entremed Inc. (Rockville, MD, 
USA).  HPLC grade methanol and acetonitrile were obtained from Mallinckrodt Baker, 
Inc (Phillipsburg, NJ, USA).  The internal standard 2ME2-d5 (2-Methoxy-17β-estradiol-
1,4,16,16,17-d5) was purchased from C/D/N Isotopes Inc. (Quebec, Canada) and its 
chemical structure is depicted in figure 3.  Water was filtered and de-ionized using Milli-
Q-UV plus system (Millipore, Milford, MA, USA).   Drug-free human plasma was 
obtained from the Blood Bank at the Warren Grant Magnuson Clinical Center (Bethesda, 
MD, USA). 
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Figure 3:  Chemical structure of the internal standard 2ME2-d5 
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Stock solutions and standards in Plasma 
Stock solutions of 2ME2 and 2ME2-d5 (IS) were made in triplicate by dissolving 
10 mg of drug in 10 mL of methanol, resulting in primary stock solutions containing 1 
mg/mL of 2ME2 and IS.  These solutions were stable and stored at -800C for up to 8 
weeks. Working solutions of 2ME2 and IS were prepared on each analysis day by serial 
dilutions in methanol from the primary stock solution.  The difference in drug 
concentration in each of the triplicate stock solutions, estimated from the mean peak area 
following repeat analysis of a dilution of the stock, was determined to be within ±5%. 
Six-point calibration samples containing 2ME2 at concentrations of 1, 5, 10, 20, 
50 and 100 ng/mL were prepared daily by addition of aliquots of the working solutions to 
drug-free human plasma.  Three pools of quality control (QC) samples for 2ME2, used 
for the evaluation of accuracy and precision, were prepared in human plasma at 
concentrations of 3, 40 and 75 ng/ml.  For freeze-thaw stability runs, the aliquots of 
prepared quality control samples were stored at -800 C. 
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Sample preparation for plasma 
A volume of 50 µL of a 1 µg/mL solution of 2ME2-d5 (IS) was added to 0.3 mL 
of plasma.  Next, 3 mL of ethyl acetate were added to the plasma sample spiked with IS.  
The mixture was then vortex-mixed for 15 minutes followed by centrifugation at 4000 
rpm for 15 minutes.  The supernatant was taken off after centrifugation and evaporated to 
dryness under a continuous stream of air at 370 C.  The extracts were reconstituted in 60 
µL of 50% methanol (in water) using vortex mixing, and 20 µL of the reconstitute was 
injected for LC/MS/MS analysis.  
 
Equipment 
Chromatography was performed on a Waters Alliance 2695 LC system (Waters 
Corporation, Milford, MA, USA), which included a quarternary pump, with an online 
degasser, a refrigerated autosampler and column compartment.  Separations were 
performed at ambient temperature on Agilent Zorbax Eclipse® XDB-C18 column (2.1 × 
50 mm i.d.; 5-µm; Waters) using a mobile phase composed of methanol and water. The 
mobile phase was delivered as a gradient run over 9 minutes at a flow rate of 0.25 
mL/min as shown in Table 6.   A Micromass Quattro Micro detector (Micromass 
Corporation, Manchester, UK) was used for tandem mass-spectrometry with atmospheric 
pressure chemical ionization source operated in the positive ionization mode.  The 
instrument was operated in the MRM (Multiple Reaction Monitoring) mode monitoring 
the ion transitions from m/z 303.1→136.8 (2ME2) and m/z 308.1→138.8 (IS).   Data 
processing and analysis were performed using Masslynx/Quanlynx software.  Detector 
settings were as follows: cone voltage, 22 V; extractor voltage, 2V; corona current, 5 µA; 
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source temperature, 1300 C; and desolvation gas flow, 310 L/h.  The zero concentration 
sample (blank) was used to visually verify the purity of the reagents and the lack of other 
potentially interfering (endogenous) substances, but was not considered for the regression 
analysis of standards.  The goodness-of-fit of various calibration models was evaluated 
by visual inspection, the correlation coefficient and a lack-of-fit test.   
 
Table 6: Mobile Phase gradient used for LC separation: 
 
 
 
Time 
(min) 
MeOH 
(%) 
Water 
(%) 
Flow 
(mL/min) 
0.0 50 50 0.25 
0.5 90 10 0.25 
5.0 90 10 0.25 
5.5 50 50 0.25 
7.9 50 50 0.25 
9.0 50 50 0.25 
 
 
Chromatography and detection in Plasma 
Typical chromatograms resulting from the LC-APCI-MS-MS analysis of 0.3-mL 
plasma extracts obtained after liquid-liquid extraction are depicted below, and include a 
blank plasma sample (Figure 4), a standard spiked at a 2ME2 concentration of 100 ng/mL 
(Figure 5), and a standard spiked at a 2ME2 concentration of 1 ng/mL (Figure 6) .  Figure 
7 depicts a chromatogram of an extract of a plasma sample obtained from a patient with 
ovarian cancer who received a single oral dose of 2ME2 at 2200 mg, before receiving the 
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dose of 2ME2 and figure 8 shows the chromatogram 0.5 hour after receiving the dose of 
2ME2.    The retention time of 2ME2 and the IS was about 5.2 minutes with an overall 
run time of 9 minutes to allow for re-equilibration of mobile phase. 
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Figure 4: Blank plasma sample (2ME2 chromatogram is depicted by 303.1 > 136.8 
transition; 2ME2-d5 chromatogram is depicted by 308.2 > 138.8 transition) 
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Figure 5:  Standard spiked at a 2ME2 concentration of 100 ng/mL (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram is 
depicted by 308.2 > 138.8 transition) 
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Figure 6:  Standard spiked at a 2ME2 concentration of 1 ng/mL (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram 
is depicted by 308.2 > 138.8 transition) 
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Figure 7: Plasma sample from patient with ovarian cancer who received a single 
oral dose of 2ME2 at 2200 mg, before receiving the dose of 2ME2 (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram 
is depicted by 308.2 > 138.8 transition) 
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Figure 8:  Plasma sample from patient with ovarian cancer who received a single 
oral dose of 2ME2 at 2200 mg, 0.5 hour after receiving the dose of 2ME2 (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram 
is depicted by 308.2 > 138.8 transition) 
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Methodology for Validation in plasma 
Method validation with respect to accuracy and precision was performed 
according to procedures described in detail elsewhere 81.  The method was validated for 
plasma in terms of linearity of detector response, accuracy, precision, sensitivity, 
specificity, freeze-thaw stability, autosampler and re-injection stability, long term 
stability and short term stability.  On each of four validation days, calibration curves were 
analyzed in duplicate along with quality control samples in replicates of five containing 
known concentrations of 2ME2.  Statistical analysis was performed using the software 
package NCSS 2001 (J. Hintze, Number Cruncher Statistical Systems, Kaysville, UT, 
USA).  The extraction recovery was calculated as a percentage by comparing the peak 
areas of samples prepared at 3 ng/mL and 75 ng/mL in human plasma and the mobile 
phase (50% acetonitrile in water) in triplicate. 
 
Response function 
Calibration curves were constructed by least-squares linear regression analysis of 
peak area ratio of 2ME2 and the IS versus the drug concentration of the nominal standard 
(x) with or without weighting. Calibration curves were fitted by weighted (1/x2) least-
squares regression analysis.  To establish the optimal quantification method and weight 
factor, the correlation coefficient of the fitted equation and the accuracy of back-
calculated calibration concentrations were taken into consideration. 
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Accuracy, precision and recovery 
Accuracy and precision were determined by analyzing quality control samples 
with 2ME2 concentrations in the low, mid and high concentration ranges of the 
calibration curve. Accuracy or percent deviation (DEV) was defined as percent difference 
between the mean observed concentration and the nominal concentration: 
%100
]nominal[
]observed[]nominal[DEV ×⎟⎠
⎞⎜⎝
⎛ −=  
Non-lower limit of quantitation (LLOQ) standards and QC samples were 
considered reliable if at least two out of every three estimates of accuracy were within the 
range of 85-115%81.   
The precision of the assay was assessed by the between-run and within-run 
precision. The between-groups mean square (MSbet), the within-groups mean square 
(MSwit), and the grand mean (GM) of the observed concentrations across run days were 
obtained by one-way analysis of variance, using the run day as classification variable.  
The between-run precision (BRP) was defined as: 
%100
GM
/)(
BRP ×−= nMSMS witbet  
where n represents the number of replicates within each validation run. The within-run 
precision (WRP) was calculated as: 
%100
GM
WRP ×= witMS  
     In order to perform the assay with reliable intermediate precision and repeatability, 
both the BRP and WRP should not exceed a 15% limit.   
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     In order to establish the extraction efficiency of 2ME2 from plasma, two groups (A 
and B) of QCs were prepared.  In group A, QCs of 3 and 75 ng/mL concentrations were 
prepared and extracted as described in sections 2.2 and 2.3.  In group B, 0.3 mL of blank 
plasma was spiked with 50 µL of IS, followed by addition of 3 mL of ethyl acetate, 
vortex-mixed for 15 minutes and centrifuged at 4000 rpm for 15 minutes.  The 
supernatant was separated and, before the drying down step, spiked with 2ME2 to result 
in concentrations of 3 and 75 ng/mL.  Samples were dried and reconstituted as described 
in section above.  Group A was designated as the extracted samples and group B was 
designated as the unextracted samples.  Samples from group A and group B were 
analyzed as described in section 3.3 and the means of peak areas of 2ME2 obtained at 
each concentration were compared to obtain % recovery at corresponding concentrations: 
% Recovery = E/U × 100 
 
where E is the mean area count of test samples for one concentration level after sample 
extraction (group A), and U is the mean area count of unextracted samples for one 
concentration (group B).  As a guidance, recovery need not be 100%, but the coefficient 
of variation should not be more than 15%.   
 
Lower limit of quantification (LLOQ) 
The LLOQ was defined as the lowest concentration of 2ME2 that could be 
reliably and reproducibly measured with values for accuracy, between-run precision, and 
within-run precision of less than 20%, with concentration determinations performed in 
quadruplicates on 4 separate occasions.  The signal-to-noise ratio ≥ 3 at the limit of 
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detection, and signal-to-noise ratio ≥ 10 at the limit of quantitation were set as 
acceptability criteria.   
 
 Specificity 
Pooled blank plasma samples were used to determine whether endogenous matrix 
constituents co-eluted with 2ME2. Blank samples were also obtained from six different 
donors, and were analyzed to determine if there were any interfering peaks around the 
retention time of 2ME2.  To rule out the specificity issues we faced with a previously 
described HPLC/UV method80, a cross-validation of the LC/MS/MS method was 
performed with a GC/MS/MS method for determination of 2ME2 in plasma developed by 
Entremed Inc. (Rockville, MD, USA).  The cross-validation samples were run in 
duplicate to determine the 2ME2 concentrations and compared to those determined by the 
GC/MS assay.     
 
Matrix Effects 
Testing for matrix effects was done by testing the signal of two groups of 
samples.  The first group of samples group A, consisted of 0.3 mL of unspiked blank 
plasma samples which were extracted using the standard liquid-liquid extraction method 
as described above.  After extraction, the aqueous phase was dried at 370 C under air until 
dryness.  The extracts were reconstituted in 60 µL of 50% methanol (in water) using 
vortex mixing and 2ME2 from the stock solution was added to it to result in 
concentrations of 3ng/mL and 75 ng/mL respectively in triplicate, and 20 µL of the 
reconstitute was injected for LC/MS/MS analysis.  The second group of samples B, 
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consisted of samples of 60 µL of 50% methanol (in water) which were spiked with 2ME2 
to result in concentrations of 3 ng/mL and 75 ng/mL in triplicate and 20 µL of the 
reconstitute was injected for LC/MS/MS analysis.  The peak areas of both groups of 
samples were compared to see if there was a significant decline in 2ME2 peak areas.  
Matrix effects were considered negligible if the peak area were within ±5% of each other. 
 
Freeze-thaw stability 
The stability of 2ME2 in plasma subjected to three consecutive freeze-thaw cycles 
(lasting 15 minutes each) was tested by quadruplicate analysis of samples containing 
2ME2 at concentrations of 3, 40 and 75 ng/mL of 2ME2. The calculated 2ME2 
concentrations were evaluated for accuracy relative to the nominal (spiked) drug 
concentration.  Analytes were considered stable if the concentration deviated less than 
±20% from the concentrations of freshly prepared samples.   
 
 Short-term and long-term stability 
The stability of 2ME2 in plasma samples stored at -800C for two weeks (short-
term stability) was tested by analysis, in quadruplicate, of samples containing 2ME2 at 3 
and 75 ng/mL.  The stability of 2ME2 in plasma samples stored at -800C for over 1 year 
at -800C (long term stability) was tested by analysis of replicates of five of samples 
containing 3 and 100 ng/mL.   2ME2 concentrations were estimated from the stored 
samples based on freshly prepared standards and were compared to freshly prepared QCs 
at concentrations of 3, 75 and 100 ng/mL.  Analytes were considered stable if the 
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concentration deviated less than ±20% from the concentrations of freshly prepared 
samples.   
 
 Autosampler and re-injection stability 
Samples were prepared in quadruplicate at 3, 40 and 75 ng/mL and left in the 
autosampler for 48 hours at 50C.   2ME2 concentrations were estimated from the stored 
samples based on freshly prepared standards and were compared to freshly prepared QCs 
at concentrations of 3, 40 and 75 ng/mL.  For re-injection stability, the remnant in the 
vials of 3, 40 and 75 ng/mL, after one injection, was re-injected and 2ME2 concentrations 
were estimated based on freshly prepared standards and were compared to freshly 
prepared QCs at concentrations of 3, 40 and 75 ng/mL. Analytes were considered stable 
if the concentration deviated less than ±20% from the concentrations of freshly prepared 
samples.   
 
Results of validation in plasma 
Specificity and cross-validation 
     Analysis of blank plasma samples obtained from multiple volunteers did not show any 
significant chromatographic interference around the retention time of 2ME2 and the IS.  
There was a small peak that co-elutes at about the same retention time as 2ME2, but the 
signal from that peak was too small to interfere with quantitation of 2ME2 at the LLOQ.  
This peak is believed to be due to carry-over of 2ME2 between samples or as a result of 
detection of endogenous 2ME2.  Seven blinded plasma samples that were previously 
quantitated by a GC/MS assay (Entremed, data on file), were analyzed using the 
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LC/MS/MS assay and the estimated concentrations were found to be comparable to those 
determined by the GC/MS assay. 
 
Response Function 
The lowest and most constant bias across the concentration range investigated 
was obtained following regression analysis of the data to a linear fit with a weighting 
factor of 1/x2  for the ratio of the peak area of 2ME2 and the IS (data not shown). For 
each analytical run, a 6-point plasma standard curve was constructed, and was shown to 
be linear over the tested range of 1 to 100 ng/mL. The mean (± standard deviation) 
regression equation obtained during the method validation, obtained in duplicates on 4 
separate occasions, showed an intercept of 0.006±0.0034 and a slope of 0.013±0.0003 
[Pearson correlation coefficient range (0.9970- 0.9753); n = 4].  
 
Lower limit of quantification (LLOQ) 
Using this procedure, the lower limit of quantification was determined to be 1 
ng/mL, with a % RSD of 19.8% and a percent deviation from the nominal standard of 
+12.1%, which was within acceptable limits.   
 
Accuracy, Precision and Recovery 
Over the entire concentration range of the standard curve, the mean observed 
percent deviation was between -8.6% and +12.1%, at an imprecision of less than 19.8% 
(Table 7). 
  
 44
Table 7 
Back Calculated Concentrations from Calibration Curves* 
 
  
Nominal GMa  SD    DEV  RSD  N 
 
(ng/mL)      (ng/mL)         (ng/mL)     (%)  
    
 
1  1.1  0.2  +12.1    0.2         9 
 
 
5  5.3  0.7  +5.2  0.1         8     
 
 
10  10.1  0.8  +1.0      0.1   8  
 
 
20  20.3  0.9  +1.63    0.04   8    
 
 
50  51.2  3.8  +2.3  0.07       8  
 
 
100  91.4  10.5  -8.6  0.11   8 
 
           
 
a Abbreviations: GM, grand mean; SD, standard deviation; DEV, percent deviation from 
nominal value; RSD, relative standard deviation; N, total number of replicate 
observations (total of all validation runs). 
 
The assay performance data for the determination of independently prepared QC 
samples of 2ME2 in plasma are presented in Table 3.3.  The between-run precision and 
within-run precision ranged from 1% to 2.8% and from 1.2% to 3.7%, respectively, for 
the various concentrations tested.  At the same QC concentrations, the values for 
accuracy were always between +5.8% and +7.9%, which is well within the generally 
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accepted limits for bioanalytical methods 81.  The extraction recovery was found to be 
86.6% and 80.5% at 3 ng/mL and 75 ng/mL respectively. 
 
Table 8 
 
Assessment of Accuracy and Precision from Quality-Control Samples: 
 
 
 
Nominal GMa  SD  DEV         WRP*      BRP     N  
 
(ng/mL)        (ng/mL)         (ng/mL)              (%)         (%)       (%)  
 
 
 
3  3.2  0.2  +7.9         3.7     2.8             20 
  
 
40  42  2.4  +4.9         1.2      2             20 
 
 
75  79.4  4.7  +5.8         2.8      1      20        
 
 
 
* - WRP was calculated from five replicates of each QC analyzed within a single day 
 
a Abbreviations: GM, grand mean; SD, standard deviation; DEV, percent deviation from nominal value; 
WRP, within-run precision; BRP, between-run precision; N, total number of replicate observations (total of 
all validation runs). 
   
Stability 
Three repeated freeze-thaw cycles of 15 minutes each, had no apparent influence 
on the stability of plasma samples containing 2ME2 at concentrations of 3, 40 or 75 
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ng/mL. After the third freeze-thaw cycle, 2ME2 plasma concentrations had mean 
deviations from the nominal values within the range of +11.2%, 12.1%, and 6.6%.  There 
was no difference in the mean peak areas after one, two, three freeze thaw cycles and 
freshly prepared samples when compared as determined using ANOVA (Table 9).  
Samples stored for two weeks (short-term stability) at -800C had mean deviations from 
nominal values within the range of 3.7% at 3 ng/mL, -0.9% at 40 ng/mL and   + 0.3% at 
75 ng/mL and were considered stable.  Samples stored for over a year (long-term 
stability) at -800C had mean deviations from nominal values of -3.8% at 3 ng/mL and 
+1.6% at 100 ng/mL and were also considered sufficiently stable.  Processed plasma 
samples were found to be stable at 50C upon standing in the autosampler tray for at least 
48 hours, allowing for overnight analysis of extracted samples.  Processed plasma 
samples that were re-injected were found to be stable at 50C upon standing in the 
autosampler tray for at least 48 hours, allowing for re-injection on extracted material, 
should that be necessary. 
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Table 9: Freeze Thaw Stability of 2ME2 
Concentration                           p-value                          F-value                    df  
(ng/mL) 
 
3                                               0.48                               0.918                       3   
40                                             0.89                               0.206                       3  
75                                             0.36                               1.219                       3 
 
a Abbreviations: df, degrees of freedom 
 
Bioanalytical method for detection of 2ME2 in human urine 
Stock solutions and standards in urine 
Stock solutions of 2ME2 and 2ME2-d5 (IS) were made in triplicate by dissolving 
10 mg of drug in 10 mL of methanol, resulting in primary stock solutions containing 1 
mg/mL of 2ME2 and IS.  These solutions were stable and stored at -800C for up to 8 
weeks. Working solutions of 2ME2 and IS were prepared on each analysis day by serial 
dilutions in methanol from the primary stock solution.  The difference in drug 
concentration in each of the triplicate stock solutions, estimated from the mean peak area 
following repeat analysis of a dilution of the stock, was determined to be within ±5%. 
For urine, calibration samples containing 2ME2 were prepared by addition of 
aliquots of the working solutions to drug-free human urine.  Calibration standards were 
prepared within the concentration range of 1 ng/mL to 30 µg/mL.  Quality control (QC) 
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samples for 2ME2 were prepared in human urine at concentrations of 3, 30, 80, 300, 750 
ng/mL, and 4 µg/mL.  Blank human urine was analyzed alongside to rule out interference 
from endogenously produced 2ME2.   
 
Sample preparation for testing amount of 2ME2 excreted unchanged in urine 
A volume of 100 µL of a 1 µg/mL solution of 2ME2-d5 was added to 1 mL of 
urine.  Next, 5 mL of de-ionized water was used to dilute the urine spiked with IS.  
Extraction was performed by addition of 5 mL of ethyl acetate.  The mixture was then 
vortex-mixed for 15 minutes, followed by centrifugation at 4000 rpm for 15 minutes.  
The supernatant was taken off after centrifugation and evaporated to dryness under a 
continuous stream of air at 370 C.  The extracts were reconstituted in 60 µL of 50% 
methanol (in water) using vortex mixing, and 20 µL of the reconstitute was injected for 
LC/MS/MS analysis.  Patient samples were analyzed on two separate occasions and the 
mean value of both runs was reported.   
 
Sample preparation for testing amount of 2ME2 excreted as glucuronides in urine  
     A volume of 100 µL of a 1 µg/mL solution of 2ME2-d5 was added to 0.5 mL of urine.  
Next, 4.5 mL of de-ionized water was used to dilute the urine spiked with IS.  After that,  
1 mL of phosphate buffer (0.1M, pH 6.5) and 80 µL of β-glucuronidase (200 units/mL) 
was added.  This mixture was incubated for 1 hour at 520 C.    Extraction was performed 
by addition of 5 mL of ethyl acetate.  The mixture was then vortex-mixed for 15 minutes, 
followed by centrifugation at 4000 rpm for 15 minutes.  The supernatant was taken off 
after centrifugation and evaporated to dryness under a continuous stream of air at 370 C.  
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The extracts were reconstituted in 60 µL of 50% methanol (in water) using vortex 
mixing, and 20 µL of the reconstitute was injected for LC/MS/MS analysis.  The amount 
of 2ME2 excreted unchanged in 24 hour urine was subtracted from the amount of 2ME2 
detected in the 24 hour urine after hydrolysis of glucuronides to obtain the absolute 
amount of 2ME2 excreted in urine as glucuronides.  Patient samples were analyzed on 
two separate occasions and the mean value of both runs was reported. 
 
 Sample preparation for testing amount of 2ME2 excreted as sulfates in urine 
     A volume of 100 µL of a 1 µg/mL solution of 2ME2-d5 was added to 1 mL of urine.  
Next, 4 mL of de-ionized water was used to dilute the urine spiked with IS.  After that,     
1 mL of acetate buffer (2M, pH 5.2) and 50 µL of sulfatase (4.9 mg protein/mL) was 
added.  This mixture was incubated for 1 hour at 520 C.    Extraction was performed by 
addition of 5 mL of ethyl acetate.  The mixture was then vortex-mixed for 15 minutes, 
followed by centrifugation at 4000 rpm for 15 minutes.  The supernatant was taken off 
after centrifugation and evaporated to dryness under a continuous stream of air at 370 C.  
The extracts were reconstituted in 60 µL of 50% methanol (in water) using vortex 
mixing, and 20 µL of the reconstitute was injected for LC/MS/MS analysis.  The amount 
of 2ME2 excreted unchanged in 24 hour urine was subtracted from the amount of 2ME2 
detected in the 24 hour urine after hydrolysis of sulfates to obtain the absolute amount of 
2ME2 excreted in urine as sulfates.  Patient samples were analyzed on two separate 
occasions and the mean value of both runs was reported. 
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Equipment 
Chromatography was performed on a Waters Alliance 2695 LC system (Waters 
Corporation, Milford, MA, USA), which included a quarternary pump, with an online 
degasser, a refrigerated autosampler and column compartment.  Separations were 
performed at ambient temperature on Agilent Zorbax Eclipse® XDB-C18 column (2.1 × 
50 mm i.d.; 5-µm; Waters) using a mobile phase composed of methanol and water. The 
mobile phase was delivered as a gradient run over 9 minutes at a flow rate of 0.25 
mL/min as shown in Table 1.   A Micromass Quattro Micro detector (Micromass 
Corporation, Manchester, UK) was used for tandem mass-spectrometry with atmospheric 
pressure chemical ionization source operated in the positive ionization mode.  The 
instrument was operated in the MRM (Multiple Reaction Monitoring) mode monitoring 
the ion transitions from m/z 303.1→136.8 (2ME2) and m/z 308.1→138.8 (IS).   Data 
processing and analysis were performed using Masslynx/Quanlynx software.  Detector 
settings were as follows: cone voltage, 22 V; extractor voltage, 2V; corona current, 5 µA; 
source temperature, 1300 C; and desolvation gas flow, 310 L/h.  The zero concentration 
sample (blank) was used to visually verify the purity of the reagents and the lack of other 
potentially interfering (endogenous) substances, but was not considered for the regression 
analysis of standards.  The goodness-of-fit of various calibration models was evaluated 
by visual inspection, the correlation coefficient and a lack-of-fit test.   
 
Chromatography and detection in Urine 
     Typical chromatograms resulting from the LC-APCI-MS-MS analysis of 1-mL urine 
extracts obtained after liquid-liquid extraction are depicted here, and include a blank 
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urine sample (Figure 9), a standard spiked at a 2ME2 concentration of 100 ng/mL (Figure 
10), and a standard spiked at a 2ME2 concentration of 1 ng/mL (Figure 11).  Figure 12 
depicts a chromatogram of an extract of 1mL of urine from a 24 hour collection, obtained 
from a patient with ovarian cancer who received a single oral dose of 2ME2 at 2200 mg, 
without addition of β-glucuronidase, figure 13 shows the chromatogram after incubation 
of urine with β-glucuronidase and figure 14 depicts the chromatogram after incubation of 
urine with sulfatase.  The retention time of 2ME2 and the IS was about 5.2 minutes with 
an overall run time of 9 minutes to allow for re-equilibration of mobile phase.  Appendix 
B contains a more comprehensive collection of the chromatograms obtained after 
analysis of 24 hour urines. 
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Figure 9: Blank urine sample (2ME2 chromatogram is depicted by 303.1 > 136.8 
transition; 2ME2-d5 chromatogram is depicted by 308.2 > 138.8 transition) 
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Figure 10:  Urine standard spiked at a 2ME2 concentration of 20 µg/mL (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram is 
depicted by 308.2 > 138.8 transition) 
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Figure 11:  Standard spiked at a 2ME2 concentration of 10 ng/mL (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram is 
depicted by 308.2 > 138.8 transition) 
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Figure 12: Urine sample from patient with ovarian cancer who received a single oral 
dose of 2ME2 at 2200 mg (2ME2 chromatogram is depicted by 303.1 > 136.8 
transition; 2ME2-d5 chromatogram is depicted by 308.2 > 138.8 transition) 
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Figure 13:  Urine sample from patient with ovarian cancer who received a single 
oral dose of 2ME2 at 2200 mg, 1 hour after treatment with β-glucuronidase (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram is 
depicted by 308.2 > 138.8 transition) 
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Figure 14:  Urine sample from patient with ovarian cancer who received a single 
oral dose of 2ME2 at 2200 mg, 1 hour after treatment with sulfatase (2ME2 
chromatogram is depicted by 303.1 > 136.8 transition; 2ME2-d5 chromatogram is 
depicted by 308.2 > 138.8 transition) 
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 Response function 
     Calibration curves were constructed by least-squares linear regression analysis of peak 
area ratio of 2ME2 and the IS versus the drug concentration of the nominal standard (x) 
with or without weighting. Calibration curves were fitted by weighted (1/x2) least-squares 
regression analysis.  To establish the optimal quantification method and weight factor, the 
correlation coefficient of the fitted equation and the accuracy of back-calculated 
calibration concentrations were taken into consideration. 
 
Specificity 
Pooled blank urine samples were used to determine whether endogenous matrix 
constituents co-eluted with 2ME2.  
 
Acceptability criteria for bioanalytical runs for analysis of 2ME2 in urine 
     The LLOQ was defined as the lowest concentration of 2ME2 that could be 
reliably and reproducibly measured on two separate occasions with coefficients of 
variation of less than 20% with concentration determinations performed in duplicates and 
a signal-to-noise ratio ≥ 3.  On each of two days along with the patient samples, 
calibration curves were analyzed in duplicate with quality control samples in replicates of 
three containing known concentrations of 2ME2.  The analytic run was considered 
acceptable only if the percent deviation (DEV) for the quality control samples were 
within  ± 20%.  Percent deviation (DEV) was defined as percent difference between the 
mean observed concentration and the nominal concentration: 
%100
]nominal[
]observed[]nominal[DEV ×⎟⎠
⎞⎜⎝
⎛ −=  
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Non-lower limit of quantitation (LLOQ) standards and QC samples were 
considered reliable if at least two out of every three estimates of accuracy were within the 
range of 80-120%81.  The accuracy and precision data as calculated from the analysis of 
2ME2 in human urine are depicted in tables 10 and 11. 
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Table 10 
 
Back Calculated Concentrations from Calibration Curves* 
 
  
Nominal GMa  SD    DEV  RSD  N 
 
(ng/mL)      (ng/mL)         (ng/mL)     (%)  
    
 
1  1.06  0.27  +6         0.25         4 
 
10  10.8  1.0  +8  0.1         6   
 
20  16.5  1.36  -17.5      0.08   6 
 
50  51.9  5.4  +3.8      0.10   6  
 
100  105.4  7.5   +5.5  0.07       6  
 
200  188.27  16.5  -5.8  0.09   6  
 
500  527.7  92.3  +5.5      0.17         6  
 
1000  935  47.1  -6.5  0.05         6  
 
3000  3047              120.9  +1.5       0.04   6  
 
5000  5003  233  +0.07       0.05   6  
 
10000  10804  187  +8.0  0.01       4  
 
20000  20842  766  4.2  0.04   4 
 
 
 
           
 
a Abbreviations: GM, grand mean; SD, standard deviation; DEV, percent deviation from 
nominal value; RSD, relative standard deviation; N, total number of replicate 
observations (total of all validation runs). 
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Table 11 
 
Assessment of Accuracy and Precision from Quality-Control Samples: 
 
 
 
Nominal GMa  SD  DEV         WRP*      BRP     N  
 
(ng/mL)        (ng/mL)         (ng/mL)              (%)         (%)       (%)  
 
 
 
30  33.2  3.1  +10.9         0.56       §             15 
  
 
80  85.7  3.1  +7.1         2.3      2.6              15 
 
 
300           322.3          28.8  +7.4         0.9      1.1      15     
 
 
800           819.8           49.1  +2.4         0.02       §             15 
  
 
4000  4099  157  +2.5         0.05    0.05             15 
 
 
 
 
 
* - WRP was calculated from five replicates of each QC analyzed within a single day 
 
§ - No additional variation was observed as a result of performing the assay on different days 
 
a Abbreviations: GM, grand mean; SD, standard deviation; DEV, percent deviation from nominal value; 
WRP, within-run precision; BRP, between-run precision; N, total number of replicate observations (total of 
all validation runs). 
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Conclusion 
     Thus, two methods were developed to for the quantitation of 2ME2 in human plasma 
and urine.  The method in plasma was fully validated and the performance criteria for 
sensitivity, accuracy, precision, linearity, stability, and specificity were acceptable, 
indicating that the method can be used for routine determination of 2ME2 in plasma 
samples obtained from patients treated with the drug.  Hence, objective # 1 of this thesis 
as listed in chapter 2 was achieved.   
     The method for detection and quantitation of 2ME2 in human urine did not receive a 
full validation.  This method was used, within the set acceptability criteria for 
bioanalytical runs, for quantitation of 2ME2 in 24-hour urine collection samples obtained 
from patients treated with the drug. 
 
 
  
 
 
 
CHAPTER FOUR   
 
PHASE I Clinical trial of Orally Administered                                                              
2-Methoxyestradiol in patients with Solid Tumors 
 
 
 
Introduction 
     The clinical experience with 2ME2 has been extensive.  Table 10 summarizes the 
results from clinical trials of 2ME2 that were completed prior to the beginning of this 
phase I clinical trial.  Because 2ME2 was tolerated well in previous clinical trials and the 
DLT had not been reached, a Phase I clinical trial was initiated at 2ME2 doses higher 
than those administered in previous clinical trials.  Following were the primary endpoints 
of this clinical trial: 
1. To characterize the side effect profile of 2ME2 
2.  To determine the pharmacokinetic profile of 2ME2 in humans 
3.  To determine if any pharmacodynamic correlations can be made between clinical  
      activity and/or toxicity 
4.   To determine the maximum tolerated dose (MTD) of 2ME2 
     The secondary endpoints of the clinical trial were: 
1. To evaluate the correlation between the rat aorta model bioassay with plasma 
concentrations of 2ME2, clinical outcome and biological endpoints 
2. To assess the changes in PET (O15 & FDG) scan during treatment with 2ME2 
3.  To assess changes in apoptosis in biopsied endothelial cells and/or tumor cells 
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     The tertiary endpoints of the clinical trial were: 
1. To determine changes in circulating molecular markers of angiogenesis following 
2ME2 therapy (TNF-α, TGF-β, bFGF & VEGF) 
2.   To determine changes in other molecular markers of angiogenesis in the biopsy  
     tissues (immunostaining for factor VIII, CD34, bFGF, VEGF, PDGF etc)  
 
  
 65
Table 12: Summary of clinical trials of 2ME2  
 
Trial Type Doses Indication Patients Comments 
Phase I 
(single agent) 
75 
200-1000 
mg/d 
Metastatic 
Breast Cancer 
31 -MTD not reached 
-No grade III/IV toxicities 
-T1/2 = 10 hours 
-All (n=3) patients receiving 
1000 mg experience hot flashes 
- Reduction in bone pain and 
analgesic use noted 
Phase I 
(with 
docetaxel:   
35 mg/m2) 
77 
200-1000 
mg/d 
Metastatic 
Breast Cancer 
15 -MTD not reached 
-No grade IV toxicities 
-Grade 3 fatigue (n=5), diarrhea 
 (n=4) and hand-foot syndrome  
 seen (n=1) 
-Grade 3 liver transaminase 
 elevations seen in 3 patients, 
 which returned to normal with 
 continued treatment 
-Extensive metabolism to 2ME1 
 was observed 
-2ME2 trough and peak levels 
 were not altered by concurrent 
 docetaxel administration 
Phase II 
(single agent) 
76 
- 400 mg/d 
       & 
- 1200 mg/d 
Hormone 
refractory 
prostate 
cancer 
33 -Well tolerated 
-PSA stabilization and declines 
were observed 
-Grade 2 and 3 liver function 
 abnormalities observed which 
 normalized after 2ME2  
 discontinuation  
-VEGF and bFGF levels 
showed and 40% and 50% 
decline respectively after being 
on therapy for 3 months 
*Abbreviations: 2ME1, 2-methoxyestrone; bFGF, basic fibroblast growth factor; MTD, maximum tolerated 
dose; PSA, prostate specific antigen; VEGF, vascular endothelial growth factor 
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Patients and Methods 
 
Patient enrollment 
 
     All patients were required to have histologically-documented solid malignancy that 
was metastatic or unresectable and for which standard treatment measures do not exist or 
were no longer effective.  Also, patients were required to have disease amenable to 
biopsy.  Patients were required to have an Eastern Cooperative Oncology Group 
performance status of 0, 1 or 2 and a life expectancy of more than 3 months.  Patients 
were excluded if they were receiving active therapy for their cancer (except patients with 
prostate cancer receiving LHRH agonists), had brain metastases and if they were 
pregnant or lactating.   
     All patients received, within 4 weeks before enrollment, baseline CT scans and 99Tc-
bone scintigraphy scans (if they had bone metastases) along with baseline PET scan (O15 
and/or FDG).  All patients had undergone a baseline tumor biopsy.  A baseline chest X-
ray and EKG were obtained at least 2 weeks before starting 2ME2.  Baseline laboratory 
studies were obtained within 7 days before starting therapy.  Follow-up laboratory studies 
were obtained at each clinic visit.  Imaging studies were repeated approximately every 2 
months.   
     Complete response was defined as compete disappearance of all tumor lesions for at 
least two measurement periods separated by 4 or more weeks; soft tissue abnormalities 
had to be re-biopsied to document absence of disease.  Partial response was defined as a 
decrease of 50% or more in the sum of the products of the longest perpendicular 
diameters of all measurable lesions or a reduction by 50% or more of the number of areas 
showing, on bone scan or CT scan lasting at least one month.  Progressive disease was 
  
 67
defined as a more than 25% increase in the sum of the products of the longest 
perpendicular diameters of all measurable lesions or the appearance of new lesions.  
Stable disease was defined a neither responding nor progressing disease for at least 6 
months after starting therapy.  Patients were removed from the study for progressive 
disease or unacceptable toxicity.  Clinically progressive disease was defined as 
development of new area of malignant disease, progression of soft tissue metastases as 
documented by appropriate modalities (imaging/palpation), at least one new metastatic 
deposit on 99Tc-bone scintigraphy or increases in tumor marker levels as per consensus 
guidelines.  Toxicity was graded by the National Cancer Institute’s common toxicity 
criteria, version 2.0.  The clinical protocol was reviewed and approved by the National 
Cancer Institute’s institutional review board.  Written informed consent was obtained 
from each patient before he or she participated in the study.   
 
Drug Administration 
     2ME2 was provided by Entremed Inc. (Rockville, MD) through the Clinical Trials 
Evaluation Program (CTEP) and was formulated as 200 mg capsules.  Patients were 
administered an initial single oral dose followed by pharmacokinetic sampling.  
Approximately one week following pharmacokinetic evaluation, daily oral dosing of 
2ME2 began.  Twenty-eight days of oral daily dosing was considered one treatment 
cycle.  If patients tolerated 2ME2 well, and did not have progressive disease, patients 
continued to receive 2ME2.   
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Study Design 
       A minimum of three patients were to be accrued at each dose level (DL) for each 
continuous 28-day cycle. Dose escalation occurred after three patients had been accrued 
and all 3 patients had undergone one cycle of treatment.  The study utilized a dose 
escalation phase I design (Table 4.1), except that the cohort size was increased to 6 
patients at any dose level if biologic activity was suggested.  If 0/3 patients experienced 
dose-limiting toxicity (DLT), and if there is no suggestion of biologic activity, then the 
subsequent 3 patients were entered at the next higher dose level.  If 0/3 experience DLT, 
but some evidence of biologic activity was suggested at a dose level, then 3 more patients 
(total 6) were to be treated at the dose level. If 1/3 patients experienced a DLT, then up to 
3 additional patients were to be entered on that dose level. If 1/6 experienced a DLT, then 
further doses were to be increased by 40%.  If 2 patients had a DLT on a dose level, then 
the dose escalation was complete; 3 additional patients were to be entered onto the dose 
level immediately below that with 2 patients having DLT, provided that only 3 patients 
were treated on that dose level.  If the dose level below that with two patients 
experiencing DLT had already entered 6 patients (with 0-1 patients having a DLT), then 
no further patients are required to establish this as the MTD.  Maximum tolerated dose 
(MTD) was defined as the highest dose level explored in which less than 2 of 6 patients 
treated for at least 28 days did not experience Grade 3 or greater non-hematologic 
toxicity or Grade 4 or greater hematologic toxicity.  Toxicity was graded by National 
Cancer Institute’s common toxicity criteria v 2.0. 
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Table 13: Dose Levels for 2ME2 clinical trial 
 
Dosage Levels Dose Patients Accrued 
1 400 mg bid 3 
2 800 mg bid 3 
3 1600 mg bid 6 
4 2200 mg bid 5 
5 3000 mg bid 3 
 
Pharmacokinetic Analysis 
     Blood samples were collected for pharmacokinetic analysis before 2ME2 
administration and then at 0.5, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 38, 50 hours after the first dose.  
At each clinic visit, at least one blood sample was obtained for pharmacokinetic analysis.  
Samples were collected in heparinized tubes and centrifuged at 2400 rpm for 5 minutes; 
plasma was aliquoted and stored at -800C until the time of analysis.  Samples were 
analyzed using a validated method based on liquid chromatography with tandem mass 
spectrometric detection (chapter 2).  Estimates of pharmacokinetic parameters were 
derived from individual concentration-time data sets by non-compartmental analysis 
using the software package WinNonlin v 4.0 (Pharsight Corporation, Mountain View, 
CA).  The peak plasma concentrations and the time to peak concentrations were observed 
values.  The area under the plasma concentration versus time curve (AUC) was calculated 
using the linear trapezoidal method from time zero to the time of the final quantifiable 
concentration (AUC[tf]).  The AUC was then extrapolated to infinity (AUC[inf]) by 
dividing the last measured concentration by the rate constant of the terminal phase (k), 
which was determined by linear-regression analysis of the final three or four time points 
of the log-linear concentration-time plot.  The apparent oral clearance (CL/F) was 
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calculated by dividing the administered dose by the observed AUC[inf] or AUClast and the 
terminal half-life (t1/2) was calculated by dividing 0.693 by k. 
 
Correlative Studies 
Frozen core biopsies were thawed in formalin and subsequently embedded in 
paraffin.  Immunohistochemistry on 4 µm tissue sections of formalin-fixed paraffin-
embedded biopsies was performed using a standard avidin-biotin-peroxidase complex 
indirect immunoperoxidase procedure as described previously 82.  Tumor content was 
evaluated with the use of hematoxylin and eosin staining.  Briefly, after deparaffinization, 
rehydration, and antigen retrieval, sections were treated with 1% H2O2 to inactivate the 
endogenous peroxidase activity and then incubated with the primary antibodies.   Mouse 
monoclonal antibodies to CD 31, clone JC70A and Ki-67, clone MIB-1 (DAKO Inc., 
Carpinteria, CA) at a dilution of 1: 20 and 1: 50, respectively, were applied to tissue 
sections at room temperature for one hour.  Binding of antibodies to their antigenic sites 
was amplified using Vectastain Elite avidin-biotin-peroxidase complex kits (Vector 
Laboratories, Burlingame, CA).  Sites of the antigen-antibody reactions were visualized 
using 3, 3-diaminobenzidine for 5 minutes and slides were counterstained with Mayer’s 
hematoxylin.  Normal tonsil known to be positive for Ki67 and breast cancer specimen 
known to be positive for CD 31 served as positive controls.  Negative controls were 
performed by omission of the primary antibodies.  Immunohistochemial staining signal 
was analyzed quantitatively with the assistance of the Automated Cellular Imaging 
System (ACIS; ChromaVision Medical Systems, Inc, San Juan Capistrano, CA).  Images 
generated by ACIS were reviewed by an investigator (S.Y.) without knowledge of any 
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clinical data.  Hot spot feature of the ACIS was used to direct to the sites of staining 
where 3 areas of tumor were scored with an X40 or a free scoring tool.  An average 
labeling percentage was reported for Ki67 and the number of vessels per mm2 for tumor 
microvessel density.   
 
Statistical Analysis 
     Spearman rank correlation analysis was performed to determine the relationship 
between the dose administered and each of the following pharmacokinetic parameters: 
peak concentration (Cmax), time to peak concentration (Tmax), half-life (T1/2), apparent oral 
clearance (CL/F), area under the plasma concentration-time curve from time zero to the 
last time point with measurable concentrations (AUClast), and the apparent volume of 
distribution (Vd/F).  In the correlation analysis, correlations such that r > 0.7 were 
interpreted as strong correlations, those with 0.5 <  r < 0.7 were moderately strong 
correlations and those with 0.3 < r < 0.5 were weak to moderate, and those with r < 0.3 
were interpreted as weak correlations.  A Jonckheere-Terpstra trend test was used to test 
if there was any trend in CL/F and Vd/F with increasing dose.  Statistical analysis was 
performed using the software package SAS Version 8.  A paired t-test was used to 
establish the statistical significance of pre and post therapy microvascular density (MVD) 
using CD 31 immunohistochemical staining and Ki67 staining.   
 
Results 
Patient Characteristics 
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     Twenty patients with advanced refractory metastatic cancer with biopsiable disease 
were enrolled onto this study (Table 14, 15).  The median age of the patients was 58 
years with a range of 37-76 years.  Patients had received a median of 4.5 prior therapies 
for their cancer with a range of 1-21 prior therapies.  The two most frequent tumor types 
were prostate cancer (n=6) and ovarian cancer (n=6).  One patient had an ECOG 
performance status of 2, seventeen were PS 1 and two were PS 0.   
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Table 14  Patient Demographics 
 
Total no.        20  
Age, years    
Median        57.5  
Range                  (37-76) 
Male:female                    11:19 
Performance status 
0                          2 
1         17 
2         1 
Primary tumor site 
Prostate        6 
Ovary         6 
Breast         1 
Melanoma        2 
Colon         1 
Sarcoma        1 
Rectal         1 
Renal         1 
Adrenal        1 
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No of Prior Therapies (including chemotherapy, hormonal and investigational agents) 
0         0 
1         1 
2         2 
≥3         17 
Median        4.5 
Range         1-21 
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Table 15: Patient Disposition 
Patient No. Cancer Gender Dose Level 
(mg/d) 
Off-study 
Reason 
Total time 
on study 
(months) 
1 Melanoma Male 800 PD 4 
2 Sarcoma Male 800 PD 1 
3 Prostate Male 800 PD 2 
4 Colon Male 1600 PD 2 
5 Breast Female 1600 PD 2 
6 Prostate Male 1600 PD 11 
7 Ovarian Female 3200 NA 40 
(ongoing) 
8 Prostate Male 3200 Tox 2 
9 Prostate Male 3200 PD 2 
10 Melanoma Female 3200 PD 2 
11 Rectal Male 3200 PD 2 
12 Ovarian Female 3200 PD 1 
13 Ovarian Female 4400 PD 2 
14 Ovarian Female 4400 PD 5 
15 Ovarian Female 4400 PD 5 
16 Prostate Male 4400 PD 3 
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17 Ovarian Female 4400 PD 2 
18 Renal cell Male 6000 PD 0.5 
19 Adrenal Female 6000 PD 4 
20 Prostate Male 6000 PD 2 
*Abbreviations: PD = progressive disease, Tox = toxicity, NA = Not applicable 
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Clinical Outcomes 
     Sixteen patients were removed from the study due to progressive disease.  One patient 
(# 7) is still receiving therapy for over three years duration at the time of this writing.  
Twelve patients remained on study for more than 60 days, seven patients remained on 
study between 31 and 60 days and one patient was taken off study within 30 days.  
Patient # 7 was a 51 year old female with history of clear cell carcinoma of the round 
ligament of the ovary diagnosed in August of 2000.  She had multiple relapses of the 
disease and had undergone total abdominal hysterectomy and bilateral salpingo-
oophorectomy and six different chemotherapeutic agents for her disease.  The patient was 
started on 2ME2 at the dose of 1600 mg q 12 h on 4/29/2002 for the treatment of lymph 
node metastases of the ovarian cancer.  The patient continues to tolerate 2ME2 well and 
continues to be on therapy for over three years at the time of this writing.  The patient 
experienced a partial response with a 78% reduction in the CA125 concentrations (Figure 
15) at the 24 month follow up and 67% reduction in the size of her pelvic lymph nodes by 
CT scan (Figure 16) and continues to receive the treatment for over 1060 days.    Fifteen 
patients were taken off the trial due to progressive disease within three months from 
initiation of therapy.  Five patients continued on the study for more than three months.  
One patient with adenocarcinoma of the prostate had stable disease based on PSA and 
continued on the treatment for 350 days. 
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Figure 15:  CA-125 concentrations versus time plot for patient #7 
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Figure 16:  CT scan of patient #7 showing shrinkage in the left pelvic lymph nodes 
after therapy with 2ME2 
 
 
 
(A) Pre-Therapy        (B)  Post-Therapy 
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Toxicities 
     2ME2 was very well tolerated at all the administered doses.  At dose level 3, one 
patient (#8) had an episode of a grade 4 angioedema 42 days (cycle 3) after starting 
2ME2.  Hence, the dose level was expanded to include a total of six patients.   
     Patient 8 was a 74 year old Caucasian male presenting with prostate cancer and ECOG 
performance of 1.  The patient was started on 2ME2 on 4/24/2002 on a dose of 1600 mg 
PO q 12 h.  On the evening of 6/5/2002, the patient began to experience tongue swelling 
and subsequent respiratory difficulty.  The patient experienced respiratory failure 
secondary to angioedema neurotica.  The patient was taken to Mercy Hospital of 
Pittsburgh Emergency Room  where, he was intubated and was treated with 
diphenhydramine hydrochloride 25 mg IV q12 h, methylprednisolone 40 mg IV q 6 hrs 
and famotidine 20 mg IV bid and was taken off 2ME2 on the same day.  This type of a 
severe allergic reaction was not an expected event and was considered unrelated to 2ME2 
administration because it occurred 38 days after the first dose of 2ME2 was administered 
and also because the patient was concurrently taking enalapril, a more likely culprit of the 
adverse event. 
     Table 16 provides a detailed synopsis of all major toxicities that occurred at each dose 
level.  Three (two male, one female) patients had hot flashes at DL 2 and 3.  Fatigue, 
diarrhea, nausea, hyperglycemia, anemia and edema were seen almost at all dose levels.  
Liver transaminases (AST, ALT) and alkaline phosphatases were elevated at higher 
doses.  There was no dose limiting toxicity (DLT) observed and MTD was not reached.   
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Table 16: Adverse Events Table 
 
                                                                          Adverse Events Reported Per Patient                                              GRADE 
 1 2 3 4 5 
ALLERGY/IMMUNOLOGY Allergic reaction/hypersensitivity (including drug fever) 1   1  
Hemoglobin 3 3 1   BLOOD/BONE MARROW Leukocytes (total WBC) 1 1    
CARDIOVASCULAR (ARRHYTHMIA) Sinus tachycardia 1     
Edema 1 2    CARDIOVASCULAR (GENERAL) Thrombosis/embolism   2   
CONSTITUTIONAL SYMPTOMS Fatigue (lethargy, malaise, asthenia) 4 3 1   
Alopecia 1     
Dry skin 2     DERMATOLOGY/SKIN 
Rash/desquamation 1 1    
ENDOCRINE Hot flashes/flushes 1 1    
Anorexia 3 1    
Ascites (non-malignant)   1   
Constipation 1     
Diarrhea patients with a colostomy 1     
Diarrhea patients without colostomy 5 2    
Nausea 7 2 1   
GASTROINTESTINAL 
Vomiting 3 4 1   
HEMORRHAGE Vaginal bleeding  1    
Alkaline phosphatase 3 1 1   
Hypoalbuminemia 1 4    
SGOT (AST) 3 1    HEPATIC 
SGPT (ALT) 2     
Hypercholesterolemia 1     
Hyperglycemia 1     
Hypermagnesemia 1     
Hypomagnesemia 3     
METABOLIC/LABORATORY 
Hyponatremia 3     
Dizziness/lightheadedness 4     NEUROLOGY 
Neuropathy-sensory 2     
Abdominal pain or cramping 1 2 1   PAIN 
Headache  2 1   
Pleural effusion (non-malignant)   1   PULMONARY 
Pneumothorax 1     
RENAL/GENITOURINARY Proteinuria 3     
SEXUAL/REPRODUCTIVE FUNCTION Male infertility  1    
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Pharmacokinetics 
     At the DL1 (400 mg) two patients had undetectable plasma concentrations of 2ME2.  
Only one patient had detectable concentrations and a peak plasma concentration of 3.9 
ng/mL was achieved after 30 minutes.  At DL2 (800 mg) two patients out of three had 
undetectable concentrations of 2ME2.  The one patient with detectable concentrations of 
2ME2 had a peak plasma concentration of 8.3 ng/mL after 4 hours.  At DL3 (1600 mg), 
five patients out of six had quantifiable concentrations of 2ME2, with a median peak 
plasma concentration of 5.7 ng/mL with a range of 3.0 ng/mL to 18.6 ng/mL, which 
occurred between 0.5 to 4 hours.  At DL4 (2200 mg), two patients out of 3 had detectable 
concentrations of 2ME2, with a median peak plasma concentration of 5.1 ng/mL and 
ranged between of 3.4 ng/mL to 7 ng/mL, which occurred between 0.5 to 6 hours.  At 
DL5 (3000 mg), two patients out of three had quantifiable concentrations of 2ME2 with a 
peak plasma concentration of 12.9 ng/mL with a range of 4.3 ng/mL to 21.7 ng/mL, 
which occurred between 2 to 6 hours.  For those patients with quantifiable 
concentrations, noncompartmental PK parameters are summarized in Table 15.  Figure 
17 through 21 below show representative concentration time profiles (as modeled by 
WINNONLIN®) in patients.   Individual concentration-time profiles are attached in 
appendix A. 
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Figure 17: Plasma concentration-time profile of a patient that received a 400 mg 
single oral dose of 2ME2 
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Figure 18: Plasma concentration-time profile of a patient that received a 800 mg 
single oral dose of 2ME2 
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Figure 19: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 20: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 21: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Table 17:  Summary of Pharmacokinetic parameters of orally administered 2ME2 
 
Dose* 400 mg 
(N=1) 
800 mg 
(N=1) 
1600 mg 
(N=5) 
2200 mg 
(N=3) 
3000 mg 
(N=2) 
Tmax (h) 0.5 4.0 1.5 (0.5-4.0) 0.5 (0.5-6.0) 4(2.0-6.0) 
Cmax 
(ng/mL) 
3.9 8.3 5.7 (3.0-
18.6) 
5.1 (3.4-7.0) 12.9 (4.3-
21.4) 
AUClast 
(ng*h/mL) 
24.6 19.4 138 (86-461) 64 (24-104) 309 (85-534)
Half-life (h) NC NC 27(24-486) 20 (1-179) 32 (18-45) 
CL/F (L/h) 9869 36815 4663 (1405-
8252) 
17572 
(6309-
81741) 
11138 
(2490-
19786) 
Vd/F (L) 78866 48172 328165 
(90554-
985782) 
529079 
(171612-
1629918) 
343520 
(163730-
523311) 
* Median (range); N = number of patients; NC, not calculated; Tmax, time to peak concentration; Cmax, peak 
concentration; AUC, area under the curve; CL/F, apparent oral clearance; Vd/F, apparent volume of 
distribution.  
 
           
     There were no dose proportional increases or correlations with Cmax (Spearman rank 
correlation coefficient r = 0.066; p=0.84) or AUClast (r = 0.22; p=0.49).  Figure 4.3 and 
4.4 depict box and whisker plots of  Cmax and AUClast, respectively, versus dose.  Except 
for a moderately strong correlation between Vd/F and dose (r =0.55; p=0.065),all other 
Spearman correlations with dose were weak, including those with Tmax, (r = 0.27; p= 
0.39),  t1/2 ( r = 0.23; p=0.48) and CL/F (r = 0.048; p= 0.88).          
     The Jonckheere-Terpstra trend test revealed that there was no trend for CL/F across 
dose levels and thus this parameter remained statistically constant with increasing dose (p 
value = 0.94).  Given the positive moderately strong correlation with dose (above), Vd/F 
was found to have a weak (although statistically insignificant) tendency toward 
increasing across dose levels (p value = 0.097).  
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     The Jonckheere-Terpstra trend test is a nonparametric test used when an ordered 
categorical parameter, such as dose level, is to be examined with regards to a trend for a 
continuously measured parameter (e.g., clearance) to increase or decrease to a statistically 
significant degree as one increases the dose level.  
H0: all clearances equal across doses;  
HA: there is a trend (up or down) in clearance as dose increases. 
     This test is a more appropriate test to use in the setting described above than either a 
Kruskal-Wallis test (or ANOVA) which merely tests if there is a global difference among 
groups, and are not sensitive to a trend in values with increasing level of the categorical 
parameter. It also is somewhat more appropriate to use in the setting described above 
than correlation analyses, since the ordered categorical values (dose levels) are limited in 
number and fixed into a small set of labeled values, while for a correlation analysis, 
normally it better to assume that both parameters being correlated are continuous and free 
to range over a wide number of values 83. 
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Figure 22: Box and whisker plots of Cmax after a single oral dose.  The box and 
whiskers represent the 10th,25th, 75th and 90th percentile of the data.  
 
Cmax Vs Dose
 
 
Figure 23: Box and whisker plots of AUClast after a single oral dose.  The box and 
whiskers represent the 10th, 25th, 75th and 90th percentile of the data.  
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     The Jonckheere-Terpstra trend test revealed that there was no trend for CL/F across 
dose levels and was thus remaining constant (p value = 0.94).  Figure 24 depicts box and 
whisker plots of  CL/F respectively versus dose.  Given the positive moderately strong 
correlation with dose (above), Vd/F was found to have a weak (although statistically 
insignificant) tendency toward increasing across dose levels (p value = 0.097).  Overall, 
the high extent of variability prevented a formal conclusion with respect to linear/non-
linear pharmacokinetic assessment. 
 
 
Figure 24: Box and whisker plots of CL/F after a single oral dose.  The box and 
whiskers represent the 10th, 25th, 75th and 90th percentile of the data. 
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       2ME2 was undetectable in plasma of two patients each at DL 1 and 2, and one 
patient each at DL 3, 4 and 5.  Circulating plasma concentrations were very low at all 
dose levels. There was extremely high interindividual pharmacokinetic variability of 
2ME2.  The drug appears to be absorbed rapidly, but incompletely.  The median plasma 
half-life was about 1-2 days, but highly variable.  The unphysiologically high values for 
oral CL/F and Vd/F reflect low oral bioavailability of 2ME2 presumably due to 
dissolution rate-limited absorption and/or extensive first-pass elimination (see chapter 5 
and 7).   
 
Urinary Pharmacokinetics of 2ME2 
     24-Hour urine collections from four patients were analyzed for the amount of 2ME2 
excreted unchanged in urine, glucuronides and sulfates (chapter 3).  2ME2 was detected 
in all four patients whose 24-hour urines were analyzed.  The median amount of 2ME2 
excreted unchanged in urine was 0.002% (0.0015-0.0075 %).  There was a significant 
increase in 2ME2 concentration detected after the treatment of patient urines with β-
glucuronidase.  The median absolute amount of 2ME2 excreted in urine as glucuronides 
was 0.81% (0.013-1.32 %).  Following table 18 provides a more detailed description of 
the above data and also provides a comparison with the Cmax obtained in each patient. 
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Table 18: Comparison of the Cmax achieved in the plasma versus the breakdown  
of excretion in urine. 
 
Patient 
 
Cmax
(ng/mL) 
% Dose 
excreted 
unchanged 
in urine 
% Dose 
excreted as 
glucuronides
% Dose 
excreted as 
sulfates 
Dose 
administered 
(mg) 
# 13 4.6 0.007 1.21 0.009 2200 
# 6 1.2 0.002 0.01 NC 800 
# 16 3.4 0.002 1.32 NC 2200 
# 15 3.2 0.002 0.39 NC 2200 
*Abbreviations: NC, not calculated; Cmax, peak concentration 
 
     The % dose excreted as sulfates of 2ME2 was not calculated for patients # 6, 15 and 
16, because there was no increase in the 2ME2 peak area as measured in the patient urine 
post-treatment with sulfatase (after de-sulfation).  At the most, about 1.4 % of the total 
administered dose of 2ME2 is accounted for in the urine.  This suggests a lack of oral 
absorption and/or excretion in the urine/bile as other unidentified metabolites.  Majority 
of the 2ME2 excreted in the urine is in the form of glucuronide metabolites and very little 
is excreted as parent compound or sulfated metabolite.  Although, the number of data 
points available here are insufficient to make this conclusion, there appears no correlation 
between the concentrations achieved in the plasma and the fraction of 2ME2 that is 
excreted in the urine as glucuronides or unchanged.  A larger sample size is required to 
make this conclusion. 
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Correlative Studies 
     Cellular proliferation occurs through a defined process in which several phases can be 
recognized. From the resting (G0) phase they join the active cycling population after 
appropriate stimuli and enter the first gap (G1) phase. Both phases have a highly variable 
duration. In G1, the cell prepares for the synthesis (S) phase, in which DNA synthesis and 
doubling of the genome take place. The S phase is followed by a period of apparent 
inactivity known as the second gap (G2) phase, in which the cell prepares for further 
separation of chromatids during the mitotic (M) phase84.  Ki67 labeling correlates with 
the S phase fraction85 and mitotic index.85,86 Using frozen sections, the Ki67 labeling 
index was prognostically relevant in several studies in invasive breast cancer 87,88.   
     Expressed on hematopoietic stem cells, CD31 is also expressed on endothelial cells 
and belongs to the immunoglobulin superfamily. It mediates adhesion between cells 
(platelets, monocytes, polymorphonuclear cells, endothelial cells, and discrete 
populations of circulating lymphocytes) that express CD31. It is an adhesion receptor 
molecule, responsible for transmitting signals through the adhesion cascade, which 
involves the integrin family of proteins.  CD 31 is generally regarded as the most 
sensitive and specific endothelial marker in paraffin sections89. 
     We performed CD 31 staining (marker of microvessel density) before and after 
therapy for seven patients, and Ki67 staining for eight patients.  Figure 25 and 26 depict 
the absolute changes in Ki67 staining and microvascular density from the baseline after 
being on therapy for at least two months.  Ki67 is a marker for cell proliferation, hence 
after treatment with a true antiproliferative agent there would be a decline in Ki67 
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staining in serial tissue biopsies.  Figure 25 shows that there was a minor decline in Ki67 
staining in three patients (# 1, 6 and 5) after treatment with 2ME2, but statistically 2ME2 
had no effect on cell proliferation by Ki67 staining (p value = 0.47; paired t-test).  
Microvessel density is a marker for angiogenesis; hence after treatment with a true 
antiangiogenic agent, there would be decrease in microvessel density in serial tissue 
biopsy staining.  Figure 26 shows that there is no noticeable decline in microvessel 
density, except for one patient (patient #9), but statistically 2ME2 had no significant 
effect on microvascular density (p value = 0.096; paired t-test) by CD 31 staining.  Thus, 
2ME2 did not produce any antiangiogenic or antiproliferative effects in the tissue 
biopsies of patients that were examined in this clinical trial.    
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Figure 25:  Changes in Ki67 staining in pretreatment tissue biopsies and after 2 
months of 2ME2 treatment 
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Figure 26:  Changes in microvessel density staining in pretreatment tissue biopsies 
and after 2 months of 2ME2 treatment 
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 Pharmacodynamic correlation 
     There were no significant adverse effects seen with 2ME2, nor there was any evidence 
of any biological activity at any dose level except for the patient with ovarian cancer who 
showed a partial response.  2ME2 also had no effect on the microvessel density and cell 
proliferation as seen with immunohistochemistry studies.  Thus, pharmacodynamic 
correlation with any drug effect was not attempted. 
 
Discussion 
     Ovarian cancer is the fifth most common form of cancer in women in the United 
states, accounting for 4% of the total number of cases and 25% of those cases that occur 
in the female genital tract and it is responsible for 5% of all cancer deaths in women 90.  
Of the various histological subtypes of ovarian cancer, clear cell carcinoma, constitutes 5-
10% of ovarian cancer.  Clear cell carcinoma is usually more resistant to systemic 
chemotherapy than other types, and has a worse prognosis 91,92.  Elevated vascular 
endothelial growth factor (VEGF) levels have been reported with epithelial ovarian 
cancer 93 and hypoxia inducible factor-1α (HIF-1α) is a transcription factor that 
modulates the transcription of VEGF 94.  2ME2 downregulates HIF-1 at the 
posttranscriptional level and inhibits HIF-1 induced transcriptional activation of VEGF 
expression 95.     
     The current study was performed to explore the safety, feasibility and 
pharmacokinetics of 2ME2 administered orally to patients with solid tumors.  In this 
study, we found that 2ME2 was very well tolerated orally at all dose levels.  There were 
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no dose limiting toxicities (DLT), and maximum tolerated dose (MTD) was not reached.  
However, there were some patients that showed evidence of hot flashes, fluid retention 
and thrombosis, typical of estrogenic compounds.  Nonetheless, there were no significant 
toxicities reported even at the highest dose levels.  2ME2 showed a very promising 
response in one patient with clear cell carcinoma of the ovary.  Four patients with ovarian 
cancer (adenocarcinomas) treated with 2ME2 at equal or higher were taken off the trial 
within less than two months because of progressive disease.  The perceived clinical 
efficacy of 2ME2 in one patient with ovarian cancer is speculated to be due to its 
histological subtype, although the clinical efficacy of 2ME2 was not reflected in the 
immunohistochemistry studies performed.  The potential role of 2ME2 in the treatment of 
ovarian clear cell carcinoma needs to be further investigated.   
     Nuclear receptors for estrogen, progesterone, and androgens are expressed in 
ovarian epithelial tumor cells. The majority of ovarian cancers express ER whereas far 
fewer tumors express PR 96. Despite high expression of ERα, the response rate to 
hormonal therapy, such as tamoxifen, in ovarian cancer is low and the lack of PR 
expression in ER-positive ovarian tumors has been suggested to indicate impaired 
estrogen action 97. It has also been suggested that expression of estrogen receptor β (ERβ) 
may contribute to determination of sensitivity to hormonal agents. ERα and ERβ have 
distinct patterns of tissue expression and can exist as homo- or heterodimers that may 
have different responses to estrogens and antiestrogens. ERβ is expressed in the normal 
ovary and most studies have found expression to either be similar or to decrease in 
ovarian tumors. By comparing receptor mRNA levels in ovarian cancer cells to those 
found in ovarian epithelial cells,  disruptions of ERα, PR, and AR mRNA expression in 
  
 100
cancer cells have been noted96.  It is suggested that progesterone and/or androgen actions 
may protect ovarian epithelial cells from neoplastic transformation 96.  Gene expression 
patterns have revealed that estrogen receptor 1 gene is expressed at relatively low levels 
in clear cell cancers, compared with other ovarian cancers98.  Overexpression of PR 
predicts a favorable outcome in patients with ovarian cancer99.  2ME2 has been recently 
shown to bind significantly to ER when used at concentrations that are cytotoxic and 
antiangiogenic 100, which may help explain the partial response seen in the patient with 
clear cell carcinoma of the ovary as compared to other ovarian cancer subtypes, which 
did not respond to 2ME2 therapy. 
     Large interpatient variability in the derived pharmacokinetic parameters exists which 
need to be further explored.  The apparent lack of dose proportionality with increasing 
doses of 2ME2 and extremely low circulating plasma concentrations point to either poor 
solubility and/or gastrointestinal permeability and/or extensive first pass metabolism 
resulting in poor and variable bioavailability.  There was no statistically significant 
increase in Cmax or AUClast of 2ME2 after administration of single oral doses ranging 
from 400 mg to 3000 mg. 
     Sulfation of estrogens is catalyzed by SULT 1E1.  Sequencing of SULT 1E1 exons 
revealed three nonsynonymous coding SNPs (cSNPs) that altered the following encoded 
amino acids: Asp22Tyr, Ala32Val and Pro253His. Among these, 12 pairs of SNPs were 
tightly linked. In addition, 12 unambiguous SULT1E1 haplotypes were identified, 
including six that were common to Caucasian and African Americans 100.  There is a two- 
to three-fold increase in K(m) values for the His253 allozyme and a greater than five-fold 
increase for the Tyr22 allozyme, thus raising the possibility of pharmacogenetic variation 
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of estrogen sulfation in different populations, and thus be a potential source of 
pharmacokinetic variability of 2ME2.   
     UGT1A1, UGT1A3, and UGT2B family of isoenzymes catalyze catechol 
estrogen glucuronidation 24,25. When the glucuronidation kinetics of expressed human 
UGTs with catechol estrogens was tested, it was found that UGT2B6(Y) reacted with a 
higher efficiency toward 4-hydroxyestrogen catechols, whereas UGT1A1 and UGT1A3 
showed higher activities toward 2-hydroxyestrogens 26. It has also been shown that 
enzymatic de-conjugation of estrogen glucuronides occurs by β-glucuronidases, and that 
it may be an important source of both primary estrogens and their catechol metabolites in 
preclinical models 27.  Pharmacogenetic variants of UGT1A1*1 and *28 and *37 have 
been shown to have altering effects on the degree of glucuronidation 100.  Thus, 
pharmacogenetic variation of different UGTs can potentially be a source of 
pharmacokinetic variability of 2ME2. 
The homozygous COMTLL allele is about 4- to 5-fold less effective in 
methylating catechol substrates in vitro as compared to the wild-type allele 101.  Serum 
levels of estradiol are significantly higher in postmenopausal women carrying the 
homozygous variant or the heterozygous (COMTHL) genotype as compared to those with 
the wild-type genotype after the oral administration of estradiol valerate tablets (dose, 2 
mg) 102. Since this COMT polymorphism correlates with decreased enzyme activity, and 
because it is a major pathway responsible for the metabolism of carcinogenic catechol 
estrogens, it is believed that the presence of the COMTLL polymorphism is associated 
with an increased risk of breast, endometrial, and ovarian cancer (see below).  Thus 
  
 102
COMT pharmacogenetics may also be a potential source of pharmacokinetic variability 
of 2ME2.   
     The bioavailability of other orally administered estrogens is known to be poor because 
of significant first pass effect 71.  There has been a widespread recognition of the 
variability in bioavailability of orally formulated cancer chemotherapeutic drugs 103.  An 
ideal chemotherapeutic drug would have little interpatient and intrapatient variability 
with successive doses.  A significant inverse correlation between decreasing absolute 
bioavailability and intersubject variability in absolute bioavailability has been established 
104.  Hence, drugs with poor bioavailability are more likely to show high interpatient and 
intrapatient variability.   
     Studies performed over the last several years have shown that the ATP-binding 
cassette transporter, ABCG2 [also known as breast cancer resistance protein (BCRP), or 
mitoxantrone resistance protein (MXR)], may be involved in transport or efflux of 
estrogens.  Biing et al 105 showed that estrogens are capable of induction of ABCB1 gene 
(previously known as MDR1), which codes for P-glycoprotein, one of the major factors 
determining multidrug resistance in cancers.   But, recent studies suggest that estradiol 
may not be a substrate for P-glycoprotein 106.  The ABCG2 gene is also highly expressed 
in several healthy organs such as the intestine 107, and it has been proposed that the use of 
specific inhibitors of this protein could be useful in making substrates orally available 108. 
Certain estrogen agonists (e.g., estriol and diethylstilbestrol) as well as antagonists (e.g., 
tamoxifen and its analogs) have been shown to reverse the ABCG2-mediated resistance 
to SN-38, mitoxantrone, and topotecan in cell culture 109.  It has been hypothesized that 
this effect of estrogens is related to a competitive inhibition of ABCG2 activity 110. In 
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addition, estrogens have been implicated in the regulation of ABCG2 protein expression 
by producing a dose-dependent decrease in mRNA levels 111. More recently, 
investigations have pointed to the notion that ABCG2 may be involved in the transport of 
unconjugated estradiol 112 as well as the sulfate-conjugates of estrone and 17β-estradiol 
113. 
     Two drug properties are of paramount importance that control a drug’s rate and extent 
of oral absorption, are solubility and gastrointestinal permeability.  2ME2 is structurally a 
steroid and falls in the Class 2 of the Biopharmaceutical Classification System 
(BCS)114,115 (see chapter 7).  2ME2 possesses characteristics of a Class 2 compound and 
exhibits poor solubility and high permeability.  The poor solubility, high permeability 
argument is reinforced by the results that have been observed in this clinical trial.  As 
indicated by very low circulating plasma concentrations of 2ME2, absence of any major 
adverse events and the results of urinary excretion pharmacokinetics, it is evident that 
2ME2 is poorly absorbed from the gastrointestinal tract.  About 1% of the total dose 
administered is recovered in the urine after 24 hours (chapter 5), which reflects the poor 
bioavailability of this compound.  2ME2 also undergoes a high hepatic first-pass effect 
(see chapter 5), which is also partly responsible for low plasma circulating 
concentrations.  High hepatic first pass effect, low plasma concentrations of 2ME2 and 
the fact that majority of 2ME2 recovered in the urine is glucuronidated, lead to the 
conclusion that high circulating concentrations of metabolites (mostly glucuronides) of 
2ME2 are very likely.  Factors responsible for the poor oral bioavailability and low 
circulating concentrations of 2ME2 are discussed in further detail in chapter 7.      
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     Collectively, the results of pharmacokinetic data supported the decision to terminate 
the study prior to reaching the primary objective of determining the MTD.  This once 
more strengthened the importance of performing pharmacokinetic analyses during a 
phase I study in order to guide the decision making process.  From an ethical point of 
view, unfavorable pharmacokinetic results should prevent unnecessary exposure of 
patients to potential harmful and less effective cytotoxic drugs.  New formulations of 
2ME2 are currently being developed with the intent of increasing oral bioavailability.   
     Thus, objective #2 and #3 of this thesis as listed in chapter 2 was achieved. Hypothesis 
#1 was established to be partly true as 2ME2 was well tolerated in the clinic but did not 
reach concentrations high enough in the plasma to have quantifiable effects on the 
markers of angiogenesis.  Hypothesis #2 proved wrong as 2ME2 did not exhibit linear 
pharmacokinetics.   
 
  
 
 
 
CHAPTER 5 
 
In vitro hepatic metabolism and in vivo elimination pathways of 2ME2  
 
 
Introduction 
     Interindividual variability in 2ME2 pharmacokinetics, toxicity and response as seen in 
Chapter 4 was extensive, and largely unexplained.  There has been a widespread 
recognition of the variability in bioavailability of orally formulated cancer 
chemotherapeutic drugs 103.  An ideal chemotherapeutic drug would have little inter-
patient and intra-patient variability with successive doses.  A significant inverse 
correlation between decreasing absolute bioavailability and intersubject variability in 
absolute bioavailability has been established 104.  Hence, drugs with poor bioavailability 
are more likely to show high interpatient and intrapatient variability.  One of the reasons 
proposed for poor bioavailability and high inter-individual variability in 2ME2 
pharmacokinetics is extensive metabolism and inter-individual variability in the rate and 
extent of 2ME2 metabolism.  The bioavailability of orally administered estrogens is 
known to be poor because of significant first-pass effect 71.  The aim of this study was to 
define the in vitro and in vivo metabolic fate of 2ME2, characterize the enzyme kinetics 
of the metabolites of 2ME2 and to estimate the total hepatic clearance of 2ME2 (CLh). 
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Materials for metabolism experiments 
Chemicals and reagents 
2ME2 (HPLC purity, 100%) was obtained from Entremed Inc. (Rockville, MD, 
USA).  Methanol (HPLC grade) and acetonitrile (HPLC grade) were obtained from 
Mallinckrodt Baker, Inc (Phillipsburg, NJ, USA).  Water was filtered and de-ionized 
using Milli-Q-UV plus system (Millipore, Milford, MA, USA).  Pooled human liver 
microsomal protein (HLM), pooled human liver S9 fraction and recombinant CYP 
isoenzymes were obtained from Xenotech (Lenexa, KS, USA).  Nicotinamide adenine 
dinucleotide (NADP+), D-glucose-6-phosphate (G6P), glucose-6-phosphate 
dehydrogenase (G6PDH), magnesium chloride (MgCl2), uridine diphosphate glucuronic 
acid (UDPGA), alamethicin (channel-forming antibiotic known to increase the 
permeability of biological membranes through the creation of transmembrane pores up to 
20 A in diameter), saccharolactone (an inhibitor of β-glucuronidases), adenosine-3’-
phosphate-5’-phosphosulfate (PAPS), β-glucuronidase and sulfatase were obtained from 
Sigma-Aldrich Co. (St Louis, MO, USA).  1M Tris buffer was obtained from Quality 
Biological Inc. (Gaithersburg, MD, USA).  2,6 Dichloro-4-nitrophenol (DCNP) was 
obtained from Alfa Aesar (Ward Hill, MA, USA).   
 
In vitro hepatic phase I metabolism experimental 
Microsomal incubations were preparing using pooled HLM protein (1 mg/mL), 
Tris-HCl buffer (100 mM, pH 7.4), 2ME2 and an NADPH-generating system containing 
magnesium chloride (4 mM).  NADPH generating system was prepared by adding        
0.5 mL of NADP+ (10 mM), 32 units of glucose-6-phosphate dehydrogenase (1300 
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U/mL),  1 mL of D-glucuose-6-phosphate (0.1 M), 900 µL de-ionized water, and 100 µL 
magnesium chloride (1 M).  Microsomal incubations without NADPH-generating system 
were used as negative controls.  Incubations were performed at 370C in a shaking water 
bath.  Reactions were terminated with the addition of twice the reaction volume of 
acetonitrile.  The reaction mixture was centrifuged at 3000 RPM for 15 minutes and the 
supernatant was analyzed by liquid chromatography method described below.  Typical 
range of substrate concentrations in in vitro metabolism experiments ranges from 0.1-100 
µM.  The linearity of metabolite formation with human liver microsomes was established 
by incubating 2ME2 at concentrations ranging from 50 nM – 1000 µM.  Metabolite peaks 
were observed only at substrate concentrations 100 µM and above due to the analytic 
limitations of the HPLC/UV method of detection.  The linear range of metabolite 
formation for substrate concentration was established between 50-300 µM.  All 
metabolite kinetics experiments were performed with 2ME2 concentration of 100 µM.  
After establishing the optimal substrate concentration, the linearity of metabolite 
formation for protein concentrations was determined using 0.2, 0.4, 0.6, 0.8 and 1 mg/mL 
concentrations of human liver microsomes.  After determining the optimal protein 
concentration, the linearity of metabolite formation for various incubation times was 
established by incubation 2ME2 with HLM protein for 0, 15, 30, 45, 60, 75, 90 and 120 
minutes.   
 
HPLC method used for metabolite quantification 
Chromatography was performed on an HP 1100 system (Agilent Technology, 
Palo Alto, CA, USA), which included a binary pump, a refrigerated autosampler, a 
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degasser and a photodiode-array detector. Chromatographic separations were performed 
at ambient temperature on a Phenomenex Prodigy (250 × 4.6 mm i.d.; 5µ PS; 
Phenomenex, Torrance, CA, USA) using a mobile phase composed of acetonitrile and 
water. The mobile phase was delivered as a gradient at 1mL/min flow rate for 40 minutes 
(Table 19), and the effluent was monitored at a UV wavelength of 205 nm.   Injection 
volume was 150 µL.  Chromatographic data were collected and analyzed using the 
Chemstation software (Agilent).  Calibration graphs were calculated by least-squares 
linear regression analysis of the peak area of 2ME2 versus the drug concentration of the 
nominal standard (x).  The concentration of metabolites produced was estimated from a 
standard curve of the parent compound 2ME2, assuming equal molar absorptivities for 
the parent 2ME2 and the metabolites.  A peak separated on HPLC was considered a 
metabolite peak if all the below criteria were satisfied: 
1.  The retention time of the metabolite peak was different from the parent 
compound or any other peaks in the background. 
2.  Peak area of the peak increased with increase in substrate concentration and 
or/time of incubation. 
3.  The peak could be successfully reproduced in at least 3 different individual 
incubations. 
4.  The metabolite peak was not produced in the negative control samples and in 
the samples of the standard curve. 
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Table 19:  HPLC gradient for metabolite quantification 
 
Time (min) % Acetonitrile % Water 
0 10 90 
3 10 90 
20 80 20 
25 80 20 
30 10 90 
40 10 90 
 
 
Metabolism of 2ME2 by human hepatic CYP 450 isoenzymes 
     Microsomal incubations were prepared using recombinant human CYP P450 
enzymes (0.22 mg/mL), Tris-HCl buffer (100 mM, pH 7.4), 2ME2 (300 µM), and an 
NADPH-generating system (prepared as described above).  Recombinant CYP isozyme 
incubations without NADPH-generating system were used as negative controls.  
Incubations were performed at 370C in a shaking water bath.  Reactions were terminated 
with the addition of twice the reaction volume of acetonitrile.  The reaction mixture was 
centrifuged at 3000 RPM for 15 minutes and the supernatant was analyzed by liquid 
chromatography method described above.  The CYP isozymes tested were CYP1A1, 
CYP 1A2, CYP 1B1, CYP 2A6, CYP 2B6, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A4, 
CYP 3A5 and CYP 2E1.  The linear range of metabolite formation for substrate 
concentration was established between 100-700 µM.  After establishing the optimal 
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substrate concentration, the linearity of metabolite formation for protein concentrations 
was determined using 0.05, 0.11, 0.22, 0.44, 0.66 and 1 mg/mL concentrations 
recombinant human CYP isozymes.  After determining the optimal protein concentration, 
the linearity of metabolite formation for various incubation times was established by 
incubation 2ME2 with HLM protein for 0, 15, 30, 45, 60, 75, 90 and 120 minutes.   
 
Enzyme Kinetics and estimation of hepatic clearance of 2ME2 
     The results obtained from in vitro metabolism experiments were model-fitted using 
the Michaelis-Menten equation and the kinetic parameters were calculated by nonlinear 
regression analysis using SigmaPlot7 (SPSS Inc, USA).  The in vitro intrinsic clearance 
(CLint) was estimated by the Vmax/Km ratio.  The predicted CLint was scaled up to in vivo 
extrapolated CLint assuming a human liver of 1.5 kg, and the conversion factor of 100 mg 
liver tissue contains 1 mg HLM protein 116.  The total hepatic clearance was calculated 
using the following formula from the well-stirred model: 
CLh = Q × fu×CLint/(Q + fu × CLint) 
Where CLh is the total hepatic clearance, fu is the free fraction of 2ME2 in plasma, CLint 
being the total in vitro intrinsic clearance (sum of all pathways).  The human hepatic 
blood flow was assumed to be 1500 mL/min and the fu of 0.27 (from chapter 6) was used 
in these calculations. 
 
Results 
In vitro hepatic phase I metabolism results 
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     After incubation of 2ME2 with HLM and NADPH generating system, there was 
appearance of four major metabolite peaks, i.e. A, B, C, D (Figure 27, 2ME2 
concentration = 200 µM) as seen after HPLC separation.  The metabolites were named A 
(TR = 14.7 minutes), B (TR = 16.3 minutes), C (TR = 17.7 minutes) and D (TR = 25.1 
minutes).  These metabolites were not produced in the negative control (Figure 5.1 B).   
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Figure 27: Chromatograms of human liver microsomal incubations of 1000 µM 
2ME2 optimized for hepatic phase I metabolism with NADPH generating system  
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Figure 28: Chromatograms of human liver microsomal incubations of 1000 µM 
2ME2 optimized for hepatic phase I metabolism without NADPH generating system  
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Michaelis-Menten Kinetics of Phase I metabolites 
     The metabolite data yielded good fits for Michaelis-Menten kinetics with a single 
binding site.  Figures 29-32 depict the Michaelis-Menten fitting of data using SigmaPlot® 
for phase I metabolites of 2ME2. 
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Figure 29:  Michaelis-Menten Kinetics for Metabolite A (symbols represent 
measured observations; curve as predicted by Michaelis-Menten Kinetics) 
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Figure 30: Michaelis-Menten Kinetics for Metabolite B (symbols represent 
measured observations; curve as predicted by Michaelis-Menten Kinetics) 
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Figure 31: Michaelis-Menten Kinetics for Metabolite C (symbols represent 
measured observations; curve as predicted by Michaelis-Menten Kinetics) 
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Figure 32: Michaelis-Menten Kinetics for Metabolite D (symbols represent 
measured observations; curve as predicted by Michaelis-Menten Kinetics) 
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Table 20 provides the apparent Km, Vmax, CLint and in vivo extrapolated CLint values for 
all the four phase I metabolites produced. 
 
Table 20: Kinetic parameters (mean estimate ± standard error) calculated from 
2ME2 incubations with HLM protein and NADPH generating system 
 
________________________________________________________________________ 
Metabolite      Km         Vmax      R2 of fit                    CLint                 in vivo  
                                                                                                                   extrapolated CLint 
           (µM)        (pmol/min*µg)                           (µL/min*µg)            (mL/min)  
________________________________________________________________________ 
 
A 90.0 ± 11.3            6.0±0.0002           0.9312              0.09      1350  
 
B 60.0 ± 5.9       3.1 ± 0.0001   0.9504           0.077      1161 
 
C 59.8 ± 4.4        3.0 ± 0.0              0.9707             0.075                 1127  
 
D      103.0 ± 14.1          9.0 ± 0.0003    0.9228          0.131      1966 
 
________________________________________________________________________ 
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Phase I metabolite identification 
     The structural elucidation of the major phase I metabolites of 2ME2 was performed by 
a collaborating laboratory using LC/MS/MS and were found to be 2-methoxyestrone 
(2ME1), 2-hydroxyestradiol (2OHE2), 2OHE1 (2-hydroxyestrone), 2, 3- dimethoxy-17β 
estradiol and 2, 3-dimethoxyestrone.  Figure 33 depicts the structures of phase I 
metabolites. 
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Figure 33:  Metabolic scheme of phase I metabolism of 2ME2 
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Metabolism of 2ME2 by human hepatic CYP 450 isoenzymes 
     After incubation of 2ME2 with recombinant CYP isoenzymes and NADPH generating 
system, metabolite peaks were seen in CYP 1A1 (Figures 34, 35), 1A2 (Figures 36, 37), 
3A4 (Figures 38, 39), 3A5 (Figures 40, 41) and 2E1 (Figures 42, 43) seen after HPLC 
separation.  Incubation of 2ME2 with CYP 1A1 produced a metabolite peak at TR = 15.1 
minutes.  Incubation of 2ME2 with CYP 1A2 produced a metabolite peak at TR = 18.7 
minutes.  Incubation of 2ME2 with CYP 3A4 produced three metabolite peaks at TR = 
16.4, 17.7 and 18.5 minutes.  Incubation of 2ME2 with CYP 3A5 produced three 
metabolite peaks at TR = 15.7, 16.4 and 17.7 minutes.  Incubation of 2ME2 with CYP 
2E1 produced two metabolite peak at TR = 17.7 and 19.5 minutes.  It was observed that 
multiple isoforms produced metabolites with the same retention times.  If we compare 
retention times of the produced metabolites, metabolite A (TR = 14.7 minutes) was not 
produced by any isoforms, metabolites B (TR = 16.3 minutes) and C (TR = 17.7 minutes) 
were produced by CYP 3A4, 3A5 and 2E1 and metabolite D (TR = 25.1 minutes) was not 
produced by any isoform Incubation of 2ME2 with recombinant CYP 1B1, 2A6, 2B6, 
2C9, 2C19 and 2D6 did not produce any metabolite (chromatograms in appendix C). 
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Figure 34:  In vitro metabolism of 2ME2 by CYP 1A1 
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Figure 35: Negative Control for CYP 1A1 incubations 
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Figure 36: In vitro metabolism of 2ME2 by CYP 1A2 
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Figure 37: Negative Control for CYP 1A2 incubations 
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Figure 38: In vitro metabolism of 2ME2 by CYP 3A4 
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Figure 39: Negative Control for CYP 3A4 incubations 
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Figure 40: In vitro metabolism of 2ME2 by CYP 3A5 
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Figure 41: Negative Control for CYP 3A5 incubations 
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Figure 42: In vitro metabolism of 2ME2 by CYP 2E1 
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Figure 43: Negative Control for CYP 2E1 incubations 
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 In vitro hepatic phase II metabolism experimental 
Uridine diphosphate glucuronosyltransferase (UGT) is localized to the 
endoplasmic reticulum (ER).  The major portion of the protein is located in the ER 
lumen, including the proposed substrate-binding domains and the catalytic site. The 
microsomal membrane impedes the access of UDPGA to the active site, resulting in 
latency of UGT activity in intact ER-derived microsomes. Active transport of UDPGA is 
believed to occur in hepatocytes, but the transport system has not been fully 
characterized.  Alamethicin, channel-forming antibiotic known to increase the 
permeability of biological membranes through the creation of transmembrane pores, has 
been shown to increase the accessibility of UDPGA to the active site.   
Microsomal incubations for glucuronidation experiments were prepared using 
pooled HLM protein (0.5 mg/mL), Tris buffer (100mM, pH 7.4), UDPGA (5mM), 
alamethicin (50 µg/mL), 1-4 saccharolactone (5mM), MgCl2 (5mM), 2ME2 (200 µM)  
and de-ionized water.  Incubations were performed at 370C in a shaking water bath.  
Microsomal incubations without UDPGA were used as negative controls.  Reactions 
were terminated with the addition of twice the reaction volume of acetonitrile.  The 
reaction mixture was centrifuged at 3000 RPM for 15 minutes and the supernatant was 
analyzed by liquid chromatography method described previously.   
The linearity of metabolite formation with human liver microsomes was 
established by incubating 2ME2 at concentrations of 50, 75, 100, 200, 300, 500, 700 and 
900 µM.  Quantifiable metabolite peaks were observed at all substrate concentrations.  
The linear range of metabolite formation for substrate concentration was established 
between 50-900 µM.  All metabolite kinetics experiments were performed with 2ME2 
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concentration of 200 µM.  After establishing the optimal substrate concentration, the 
linearity of metabolite formation for protein concentrations was determined using 0.2, 
0.4, 0.6, 0.8, 1 and 1.2 mg/mL concentrations of human liver microsomes.  After 
determining the optimal protein concentration, the linearity of metabolite formation for 
various incubation times was established by incubation 2ME2 with HLM protein for 0, 
15, 30, 45, 60, 75, 90, 120 and 150 minutes.   
Microsomal incubations for sulfation experiments were prepared using pooled 
human liver S9 fraction protein (0.5 mg/mL), Tris buffer (100mM, pH 7.4), PAPS (400 
µM), 2ME2 and de-ionized water.  Microsomal incubations with DCNP (10 µM) were 
used as negative controls.  Incubations were performed at 370C in a shaking water bath.  
Reactions were terminated with the addition of twice the reaction volume of acetonitrile.  
The reaction mixture was centrifuged at 3000 RPM for 15 minutes and the supernatant 
was analyzed by liquid chromatography method described previously.   
 
In vitro phase II metabolism results 
     After incubation of 2ME2 with the system optimized for glucuronidation, there was 
appearance of two major metabolites, i.e. G 1 and G 2 (Figure 44, 2ME2 concentration 
200 µM) as seen after HPLC separation.  These metabolites were not produced in the 
negative control (Figure 45).   
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Figure 44:  In vitro glucuronidation of 2ME2 in human liver microsomes 
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Figure 45: Negative control for in vitro glucuronidation of 2ME2 in human liver 
microsomes 
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Michaelis-Menten Kinetics of glucuronides of 2ME2 
     The metabolite data yielded good fits for Michaelis-Menten kinetics with a single 
binding site.  Figures 46 and 47 depict the Michaelis-Menten fitting of data using 
SigmaPlot® for glucuronides of 2ME2. 
 
 
Figure 46:  Michaelis-Menten Kinetics for Glucuronide 1 produced after incubation 
of 200 µM 2ME2 in human liver microsomes (symbols represent measured 
observations; curve as predicted by Michaelis-Menten Kinetics) 
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Figure 47:  Michaelis-Menten Kinetics for Glucuronide 2 produced after incubation 
of 200 µM 2ME2 in human liver microsomes (symbols represent measured 
observations; curve as predicted by Michaelis-Menten Kinetics) 
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Table 20 provides the apparent Km, Vmax, CLint and in vivo extrapolated CLint values for 
the two glucuronides of 2ME2. 
 
Table 20: Kinetic parameters (mean ± standard error) for two glucuronides of 
2ME2 
________________________________________________________________________ 
Glucuronide Km          Vmax      R2 of fit               CLint                   in vivo  
                                                                                                                  extrapolated CLint 
           (µM)    (µmol/min*mg)                      (mL/min*mg)                   (mL/min)  
________________________________________________________________________ 
 
1 90.3± 22.9      0.215 ± 0.012        0.8428              3.58              53700 
 
2 92.8 ± 30.2 0.065 ± 0.004       0.6002              1.06             15898 
________________________________________________________________________ 
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Results of sulfation experiments 
 
     After incubation of 2ME2 with system optimized for sulfation, there was no  
appearance of new metabolite peaks at the end of one hour incubation period.  There was 
no significant difference between peak area of 2ME2 measured in incubations with  
PAPS, with DCNP (inhibitor of sulfation) and without PAPS. These results were  
reproduced at three separate occasions where each sample was analyzed in duplicates.   
Figure 5.11 depicts the chromatogram obtained after incubation of 2ME2 for sulfation  
with PAPS (Figure 48) and without PAPS (Figure 49). 
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Figure 48:  In vitro sulfation of 2ME2 with human liver S9 fraction 
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Figure 49: Negative control for in vitro sulfation of 2ME2 with human liver S9 
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Estimation of total hepatic clearance 
     All in vitro intrinsic clearances (CLint) reported above in Table 18 and 19 for the 
metabolites A, B, C, D, G 1 and G 2 were extrapolated to estimate the in vivo CLint 
(mL/min) for a human liver of 1.5 kg.  The assumption used for scaling was 100 mg 
human liver contains 1 mg of human liver microsomal protein.  The total in vivo, 
extrapolated CLint of 2ME2 for a human liver was calculated as the sum of all individual 
in vivo extrapolated CLint.  The total in vivo extrapolated CLint thus obtained was used in 
the equation of the well-stirred model to obtain total hepatic clearance (CLh).  The total 
hepatic clearance was reported to be 862 mL/min.  This number is more than half of 
hepatic blood flow which is assumed to be 1500 mL/min or 750 mL/min of plasma.  The 
CLh is calculated in relation to plasma.  Hence, CLh of 2ME2 exceeds the flow of plasma 
through the liver.  This suggests that 2ME2 is a high-extraction ratio drug.  This number 
is believed to be an underestimation because biliary excretion after hepatic metabolism is 
assumed to be negligible.  Also, glucuronidation of phase I metabolites is not taken into 
account.  We have reported low circulating concentrations of 2ME2 in the human plasma 
after administration of high doses orally (chapter 4).  This finding corroborates the 
observation of poor circulating concentrations of 2ME2 after oral absorption, thus 
indicating that 2ME2 has poor oral bioavailability and high first-pass effect is one of the 
major factors determining its oral bioavailability. 
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Characterization of in vivo elimination pathways for 2ME2 
Calculation of metabolic ratio 
     The metabolic ratio for glucuronides and sulfates in the urine was calculated using the 
following formula: 
⎟⎟⎠
⎞⎜⎜⎝
⎛=
unchanged excreted 2ME2 ofAmount 
)de/sulfate(glucuroni conjugate as excreted 2ME2 ofAmount  RatioMetabolic  
 
     Following table 22 provides the metabolic ratios as calculated from the data obtained 
after analysis of 24-hour urine samples: 
 
Table 22:  Metabolic ratios 
 
Patient Metabolic Ratio for 
glucuronidation 
Metabolic Ratio for 
sulfation 
#13 162 1 
#6 7 NC 
#16 634 NC 
#15 251 NC 
*Abbreviations: NC, not calculable 
      
     Thus, 2ME2 was excreted in the urine predominantly as glucuronides.  Very little 
amount was excreted unchanged or as sulfates. 
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Discussion 
     Glucuronidation by uridine-5’-diphosphate glucuronosyltransferase (UGT) of 
estrogens is generally accepted to play a principal role in elimination pathways followed 
by excretion of the conjugates through urine and feces. Results of previous studies 
indicate that the UGT1A1, UGT1A3, and UGT2B family of isoenzymes catalyze 
catechol estrogen glucuronidation 24,25.  The two major glucuronides of 2ME2 are G1 and 
G2.  The total CLint for glucuronidation pathways is at least 12,000 fold the total CLint  
for the hepatic phase I metabolism pathways, and the total in vivo extrapolated CLint for 
all glucuronidation pathways is at least 12 fold the total in vivo extrapolated CLint for all 
hepatic phase I metabolism pathways.   Hence, we conclude that the predominant route of 
metabolism for 2ME2 is through glucuronidation and subsequent excretion in urine and 
through biliary excretion in feces.  The reported apparent Km values for glucuronidation 
of  estradiol in human liver microsomes was 17 µM for the 3-glucuronide of estradiol and 
6 µM for the 17β-glucuronide of estradiol 117.  The apparent Km values reported for 
human hepatic glucuronidation of ethinyl estradiol is 200 ± 120 µM 118.  The Km obtained 
for glucuronidation of 2ME2 was significantly higher than the previously reported values 
for estradiol glucuronidation, but was more akin to the apparent Km values obtained from 
ethinyl estradiol glucuronidation, taking the standard deviation into account.  Hence, 
2ME2 seems to have lesser affinity for hepatic glucuronosyltransferases as compared to 
estradiol.  The reported apparent Vmax values for glucuronidation of  estradiol in human 
liver microsomes was 0.40 nmol/mg/min for the 3-glucuronide of estradiol and 0.32 
nmol/mg/min for the 17β-glucuronide of estradiol 117.  The Vmax values that we report for 
glucuronidation of estradiol in human liver microsomes are about 150-fold higher for G2 
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and 500 fold higher for G1.  The differences in Vmax are attributed to the higher amounts 
of substrate and microsomal protein used in our experiments along with the differences in 
the analytical method used for quantification of metabolite concentrations, higher 
amounts of cofactors (Mg+2, alamethicin, saccharolactone) used in our experiments.  But, 
the calculated Clint values for 3-glucuronide of estradiol by was 23.5 ml/min/mcg and for 
17-glucuronide of estradiol was 53.5 ml/min/mcg which are 20,000-50,000 fold higher 
than that reported by us for 2ME2.  Thus, 2ME2 has a very low Clint as compared to 
estradiol. 
          Hepatic phase I metabolism also plays a major role in the metabolism of 2ME2 
resulting in the production of 2ME1, 2OHE2, 2OHE1 and 2, 3- dimethoxy-17β estradiol 
and 2, 3-dimethoxyestrone.  Much like other estrogens, the major CYP isoenzymes 
responsible for the metabolism of 2ME2 are CYP 1A1, 1A2, 3A4, 3A5 and 2E1.  The 2-
hydroxylation of estradiol and estrone, catalyzed by the CYP1A1/2 and CYP3A isozymes 
7-9, is the major metabolic pathway in the liver as compared to the 4-hydroxylation, which 
is exclusively catalyzed by CYP3A 10. The 2-hydroxyl metabolites of estradiol and 
estrone are further metabolized by a catechol-o-methyl transferase (COMT), which 
converts these products to 2-methoxyestradiol (2ME2) and 2-methoxyestrone, 
respectively.  The reported apparent Km values for E2 hydroxylation catalyzed by the 
human cytochrome P450 isoenzymes range from 20-156 µM 119.  All Km values that we 
report for phase I reactions fall within the range of previously reported values for 
estradiol hydroxylation.   
     Sulfation of steroids is an important biotransformation step involved in the regulation 
of tissue specific estrogen levels, majority of which is believed to take place in the 
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gastrointestinal tract.  Sulfation is known to be a high affinity, low capacity type reaction.  
SULT 1E1 catalyzes the sulfation of 17β-estradiol.  Unlike other estrogens, 2ME2 was 
not metabolized through sulfation in the in vitro system, which was further corroborated 
by the results obtained in human urine after administration of 2ME2 orally.   
Sulfotransferase enzymes catalyze the transfer of SO3- from 3’-phosphoadenosine-5’-
phosphosulfate, the enzymatic cofactor, to phenolic acceptor groups on estrogens.  17β-
Estradiol and estrone are sulfated at the 3-position to 17β-estradiol 3-sulfate and estrone 
3-sulfate 120.  Estrogens are sulfated predominantly at the 3-position and not at 17β 
position which is adjacent to a methyl group; unlike glucuronidation which can occur 
either at the 3 or 17β hydroxyl group of steroid hormones 21.  2ME2 has a methoxy group 
at C-2 position, which might be responsible for producing steric hindrance large enough 
to hamper sulfation.  The half-life of sulfates is much longer in the plasma as compared 
to glucuronides, and a larger proportion of sulfates are excreted into the bile as compared 
to urine, which might have been responsible for undetectable sulfate conjugates in vivo in 
the urine of three patients.  
     The CLh was calculated as 862 mL/min, which is more than half of the liver blood 
flow.  The liver plasma flow is about 750 mL/min, since blood consists of essentially 
50% plasma.  The actual CLh may approximate the hepatic blood flow making 2ME2 a 
high extraction ratio drug, thus partly explaining the poor bioavailability of 2ME2.  The 
calculated CLh is believed to be an underestimation of the actual CLh of 2ME2, because 
our calculation does not account for biliary excretion of 2ME2 in feces and the 
glucuronidation of phase I metabolites of 2ME2, which might be significant considering 
that there are at least four major metabolites produced by hepatic phase I metabolism.   
  
 148
     Thus, it is concluded from this study that the major route of metabolism of 2ME2 is 
through glucuronidation and excretion in urine and feces.  Glucuronidation of orally 
administered 2ME2 most likely occurs during the gastrointestinal/hepatic first pass and 
during enterohepatic recirculation, if it exists.  The high first pass effect for 2ME2 may 
be one of the reasons responsible for the very low circulating concentrations of 2ME2 
observed in patients (chapter 4).  The glucuronides of 2ME2 may also be responsible for 
the long half life of 2ME2 in plasma.  The glucuronides are excreted in the bile thus 
subjecting 2ME2 to the possibility of enterohepatic recirculation (as seen with other 
estrogens), and also to ‘cycling’ of estrogens as described in chapter 1, thus prolonging 
its half life.  The patient with ovarian cancer who showed a partial response on treatment 
with 2ME2 had very low circulating concentrations of 2ME2.  One of the reasons 
proposed for this observation is that an active metabolite of 2ME2 may be responsible for 
its antitumor activity.  Further studies need to be done to identify the antitumor activity of 
the metabolites of 2ME2.  Sulfation does not seem to play a major role in the renal 
excretion of 2ME2, thus disproving the hypothesis #4 as listed in chapter 2.  The 
metabolic fate of orally administered 2ME2 was established and thus the objective #5 as 
listed in chapter 2 was achieved.   
      
  
  
CHAPTER SIX 
 
Plasma Protein Binding studies of 2-Methoxyestradiol in Human Plasma                                     
 
 
Introduction 
     The pharmacokinetic evaluation of 2ME2 given orally to cancer patients has shown a 
considerably long terminal half-life of 2ME2 in plasma (approximately 1-2 days), in spite 
of having low circulating plasma concentration (chapter 4).  The basis for this long half-
life in humans may possibly be related to enterohepatic recirculation processes.  
However, a variety of other factors may influence the prolonged circulation of 2ME2 in 
humans, including binding of the compound to plasma proteins. Indeed, drugs with high 
affinity for plasma proteins often demonstrate a relatively slow distribution and 
elimination of drug from the central compartment, which may prolong the apparent half-
life.  Estrogens have been known to bind primarily to albumin and sex hormone binding 
globulin (SHBG).  Dunn et al72 have established that in human females 37 % of estradiol 
is SHBG bound, 61% is albumin bound and 1.8% is free while in human males 78 % of 
estradiol is albumin bound, 20% is SHBG bound and 2.3% is free.   
     The purpose of this study was to characterize the binding properties of 2ME2 to 
human plasma and individual proteins using a novel microequilibrium dialysis method 
that might help better explain the pharmacokinetics of this compound. 
Materials and methods 
Chemicals and reagents 
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     2-methoxyestradiol (chromatographic purity, 99.99%) and [3H]-2ME2 (specific 
activity, 5 Ci/mmol) were kindly supplied by Entremed Inc. (Rockville, MD, USA).  
HPLC-grade methanol, ethanol and acetonitrile were obtained from J. T. Baker 
(Phillipsburg, NJ, USA). De-ionized water was generated with a Hydro-Reverse Osmosis 
system (Durham, NC, USA) connected to a Milli-Q UV Plus purifying system 
(Marlborough, MA, USA). Bio-Safe II scintillation fluid was obtained from Research 
Products International (Mount Prospect, IL, USA).  Albumin, α1-acid glycoprotein 
(AAG), sex-hormone binding globulin (SHBG) and 2-methoxyestrone (2ME1) were 
obtained from Sigma-Aldrich Inc, USA.  Other chemicals were of reagent grade or better.  
Pure protein solutions at respective physiological concentrations were prepared in 0.01 M 
phosphate buffer (pH 7.4).  The stock solutions of all test substances were made in 
ethanol.  Drug-free human plasma was obtained pre-dose samples of cancer patients 
receiving 2ME2, and the plasma fraction was separated by centrifugation (3000 × g for 5 
min at 37 °C), and frozen within 1 hour after collection.  Drug-free heparinized human 
plasma from healthy volunteers was obtained from the National Institutes of Health 
Clinical Center Blood Bank (Bethesda, MD, USA). 
 
Development and validation of dialysis method 
     Equilibrium dialysis was performed on a plate rotator (Model # 74-2334, Harvard 
Apparatus, Holliston, MA, USA) at 37°C in a humidified atmosphere of 5% CO2 using 
96-wells micro-dialysis plates (Harvard Apparatus) 121. The dialysis compartments in 
each well are separated by a regenerated cellulose membrane with a 5-kDa cut-off. 
Experiments were carried out with 250-µl aliquots of plasma containing a tracer amount 
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of [3H]-2ME2 (5µL of 0.02 mCi/mL) against an equal volume of 0.01 M phosphate 
buffer (pH 7.4).  Drug concentrations in 125 µl-aliquots of both compartments were 
measured by liquid scintillation counting (LSC) for 1 minute following the addition of 
Bio-Safe II scintillation fluid on a Model LS6000IC counter (Beckman Instruments, Inc., 
Columbia, MD). 
 
Method Validation 
Precision 
The precision of the assay was assessed by calculation of the between-run and 
within-run precision. The between-groups mean square (MSbet), the within-groups mean 
square (MSwit), and the grand mean (GM) of the observed concentrations across run days 
were obtained by one-way analysis of variance, using the run day as classification 
variable.  The between-run precision (BRP) was defined as: 
%100
GM
/)(
BRP ×−= nMSMS witbet  
where n represents the number of replicates within each validation run. The within-run 
precision (WRP) was calculated as: 
%100
GM
WRP ×= witMS  
     The precision was assessed by analyzing quadruplicate samples prepared from 4 
different plasma sources in quadruplicate on 4 separate occasions. Within- and between-
assay precision estimates were obtained by one-way analysis of variance, and reported as 
relative standard deviation.   
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Specificity 
 To evaluate the specificity of this procedure and check for displacement effect of           
2-methoxyestrone (2ME1) on protein binding of 2ME2, blank human plasma was spiked 
with  10 ng/mL, 100 ng/mL, 500 ng/mL, 800 ng/mL, 1 µg/mL, 10 µg/mL, 40 µg/mL and 
analyzed in quadruplicate for changes in the fraction unbound drug (fu).   
 
Stability and Recovery 
     The stability of [3H]-2ME2 at 370C was assessed in human plasma and 0.01 M 
phosphate buffer (pH 7.4) by comparing in quadruplicates the liquid scintillation counts 
obtained after 24 hours to freshly prepared samples.  The stability of 2ME2 in plasma at 
370C  was analyzed by comparing peak area in quadruplicates of 1ng/mL (LLOQ) of 
2ME2 in plasma kept for 24 hours using an LC/MS/MS method 122 to freshly prepared 
samples.  Freeze-thaw stability of [3H]-2ME2 was established by comparing in 
quadruplicate, the liquid scintillation counts obtained by plasma samples spiked with 
[3H]-2ME2 after one freeze-thaw cycle, with freshly prepared plasma samples with equal 
amount of [3H]-2ME2.  Freeze-thaw stability of 2ME2 in plasma has been established 
elsewhere 122.  Samples were considered stable if the difference between peak areas (for 
2ME2 in plasma) and liquid scintillation counts (for [3H]-2ME2 in Plasma or buffer) was 
within ±20%. 
     In order to calculate the recovery, two groups of samples (group A and B) were 
prepared in replicates of eight.  In group A, plasma and 0.01 M phosphate buffer (pH 7.4) 
from both sides of the equilibrium dialysis well (~500 µL), were completely emptied into 
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the scintillation counting fluid.  In group B, were freshly prepared samples with 250 µL 
of PBS and 250 µL of plasma with 5 µL of [3H]-2ME2 (0.02 mCi/mL).  Recovery was 
calculated using the following formula: 
 
          100
A GroupCount  ionScintillat
 BGroupCount  ionScintillat Recovery % ×=  
 
Time to Equilibrium and Saturation of PPB in healthy human plasma 
     The time course of equilibrium was assessed in quadruplicate at 0.5, 1, 1.5, 2, 3, 4, 5, 
6, 18, 22, 24 and 30 and 48 hours after start of the experiment.  The determination of fu 
was also performed in plasma samples from healthy human volunteers over the 
anticipated clinically relevant concentration range of 2ME2 (0, 1, 5, 10, 15, 20, 30 
ng/mL) and at concentrations higher than that at 40, 100 and 400 ng/mL to test 
saturability of plasma protein binding.   
 
In vitro binding to purified human plasma proteins 
     The binding of 2ME2 to purified human proteins was studied by testing various 
protein concentrations in triplicate in 0.01 M phosphate buffer (pH 7.4).  Albumin 
binding was studied within the concentration range of 1-5 g/dl (physiological range: 3.5-
4.5 g/dL), AAG  binding was studied within the concentration range of 0.01-0.25 g/dL 
(physiological range: 0.1-0.25 g/dL) and SHBG binding was studied within the 
concentration range of 10-200 nM (physiological range: 13-130 nM). 
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Ex-vivo plasma protein binding experiments 
Patients and treatment 
     Plasma samples from 5 patients, who received single oral doses of 2ME2 orally, were 
used to determine the in vivo unbound fraction of 2ME2 in cancer patients.  From each 
patient, serial plasma samples were obtained during the first course of treatment at the 
following time points: (i) immediately before drug administration (pre-dose), and (ii) at 
0.5, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 38 and 50 hours after the first drug administration. All 
blood samples were immediately placed in an ice-water bath, centrifuged within 30 
minutes of collection at 1000 × g for 10 min at 4°C, and were stored at or below –70 °C 
until analysis. 
 
Measurement of total drug concentrations 
     Total 2ME2 concentrations were determined using a validated analytical method 
based on liquid chromatography coupled tandem mass spectrometric detection as 
described in chapter 2 122. 
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Measurement of unbound drug concentrations 
     The fraction unbound (fu) 2ME2 in each individual patient plasma sample was 
determined using equilibrium dialysis, and samples were analyzed for total radioactivity 
(i.e., [3H]-2ME2) by liquid-scintillation counting as described above.  The unbound drug 
concentrations (Cu) were calculated from the fraction unbound drug (fu) and the total drug 
concentration in plasma (Cp) (i.e., the total of unbound and protein bound), as Cu = fu × 
Cp. 
 
Pharmacokinetic analysis 
     Estimates of pharmacokinetic parameters for total and unbound 2ME2 in plasma were 
derived from individual concentration-time data sets by noncompartmental analysis using 
the software package WinNonlin v4.0 (Pharsight Corporation, Mountain View, CA, 
USA). The area under the plasma concentration-time curve (AUC) was calculated using 
the linear trapezoidal method from time zero to the time of the final quantifiable 
concentration (AUC[tf]). The AUC was extrapolated to infinity by dividing the last 
measured concentration by the rate constant of the terminal phase (k), determined by log-
linear regression analysis. The apparent oral clearance (CL/F) was calculated by dividing 
the administered dose by the observed AUC [inf], and the terminal half-life was 
calculated as ln2/ k. 
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Statistical considerations 
     All binding experiments were performed at least in triplicate on at least 3 separate 
occasions, and statistical analyses were carried out using NCSS v2001 (J. L. Hintze, 
Kaysville, UT, USA).  The effects of 2ME2 concentration, protein concentrations on drug 
binding were estimated by a one-way ANOVA.  All data are presented as mean values ± 
standard deviation (SD), unless stated otherwise, and for all tests the a priori cutoff for 
statistical significance was taken at p-value < 0.05. 
 
Results  
Validation of dialysis method for 2ME2 
     Preliminary experiments revealed that equilibrium was attained approximately 24 
hours (Fig 50).  The data were modeled using Graphpad Prism version 2.0.  The mean 
coefficient of variation of all sample values was less than 20%, assuring high 
discriminatory power in the detection of changes in fu for 2ME2 in patient samples. With 
the final method, the within-run and between-run variability were 7.1% and 8.5% 
respectively.  2ME1 (10 ng/mL - 10µg/mL) did not change the fraction unbound for 
2ME2 (p value > 0.05).  [3H]-2ME2 was found to be stable in plasma and PBS at 370 C 
for 24 hours.  [3H]-2ME2 was found to be stable in plasma after one freeze thaw cycle.  
The % recovery for [3H]-2ME2 was found to be 92%.  Hence, we can conclude that there 
is negligible amount of nonspecific binding of 2ME2. 
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Figure 50: Time course to reach equilibrium for the fraction unbound 2ME2. Data 
are presented as means of individual observations (symbols) and a predicted  
model fit according to a modified Hill function (R2 = 0.85) with standard  
deviations (error bars). 
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In vitro binding interactions with 2ME2 
     2ME2 was found to bind highly to human plasma (mean, 97.4 ± 0.2 %), with a free 
drug fraction of (2.7 ± 0.2 %).  There was no significant source difference in fu when 
plasma was used from different healthy individuals (mean fu, 2.68; p-value > 0.05; one- 
way ANOVA). The fu obtained in previously frozen plasma from healthy volunteers was 
found to be slightly higher than that observed in the plasma from six cancer patient (mean 
fu, 1.9 % versus 2.6%; p value = 0.045).  
     At clinically relevant concentrations of 2ME2 (1 to 30 ng/mL), the binding was 
concentration-independent (P > 0.05), indicating a low-affinity, possibly non-specific and 
non-saturable process.  Figure 51 depicts the relationship between bound and unbound 
concentrations of 2ME2. 
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Figure 51: Binding of 2ME2 to human plasma  
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There is a linear relationship between bound and unbound 2ME2 concentrations 
(R2 = 0.99).  The binding characteristics of 2ME2 in human plasma were further 
examined by plotting the ratio of Cb/Cu versus Cb in plasma.   
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Figure 52:  Plot of 2ME2 Cb/Cu versus Cb in plasma from healthy human 
 volunteers 
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Above figure 52 shows the plot of the ratio of bound and unbound 2ME2 
concentrations versus bound 2ME2 concentration.  The slope of linear regression in the 
above not significantly different from zero (p-value = 0.57).  Hence, the binding of 2ME2 
is non-saturable in the therapeutically achievable range.    
2ME2 binding to albumin (1 – 5 g/dL), α1-acid glycoprotein (0.1-0.25 mg/dL), 
and sex-hormone binding globulin (1-20 µg/mL) was found to be protein concentration-
dependent, i.e., fu decreased with increase in protein concentration (p-value < 0.05; one-
way ANOVA).   Table 23 provides a detailed synopsis of the effect of concentration of 
different proteins on fu (%) of 2ME2.  Figure 53 provides a histogram comparing the 
binding of 2ME2 with HSA (53A), AAG (53B) and SHBG (53C) at different 
concentrations. 
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Table 23  Binding of 2ME2 to purified human proteins 
 
 
Protein   Concentration            Mean fu (%)         N  
 
 
Albumin  50 mg/mL      3.1                  3      
 
Albumin  40 mg/mL      3.8                  3      
 
Albumin  25 mg/mL      5.3                  3    
 
Albumin  10 mg/mL      10.5                  3 
________________________________________________________________________ 
 
 
AAG       2.5 mg/mL      27.6                  3     
 
AAG   1 mg/mL     48.8                  3     
 
AAG   0.5 mg/mL      63.4                  3     
  
AAG   0.1 mg/mL      81.5                  3 
_______________________________________________________________________     
 
 
SHBG   20 µg/mL      73.3                  2     
 
SHBG   5 µg/mL      85.5                  3     
 
SHBG   1 µg/mL      92.6                  3      
     
 
*Abbreviations: AAG, α-1 acid glycoprotein; SHBG, sex-hormone binding globulin; fu, fraction unbound ; 
N, number of replicate observations  
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Fig 53: Binding of 2ME2 to human plasma proteins. Data are presented as mean 
values (bars) ± SD (error bars).  
 
Figure 53 (A): Binding of 2ME2 with human serum albumin (1-5 g/dL) 
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(B) Binding of 2ME2 with human serum α1-acid glycoprotein (0.01-0.25 g/dL) 
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(C) Binding of 2ME2 with human sex-hormone binding globulin (10-200 nM) 
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Estimation of binding parameters 
     Estimation of binding parameters to individual proteins was performed using the data 
obtained from buffer solutions of purified human proteins. The drug concentration ratio 
in the buffer protein solution after dialysis was calculated for each paired observation, 
and was taken as an estimate of the unbound drug fraction (fu). The bound drug fraction 
(fbd) was calculated as fbd = (1 – fu).  The total binding constants (nK) for the drug 
interactions with isolated proteins (HSA, AAG and SHBG) was calculated using the 
following equation, assuming a single class of nonsaturable binding sites and no 
allosteric effects: 
                                                                                                    CuPnKCb ⋅⋅=
PnK
fu ⋅+= 1
1                                                                                                               
where P is the protein concentration, (Cu) is unbound drug concentration, (Cb) is bound 
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drug concentration, nK (product of number of binding sites by affinity constant) denotes 
the total binding constant.  Here nK*P is the slope of the regression line, Cbd, Cu and P 
are expressed as molar concentrations (M-1).  
fb = 1-fu PnK ⋅+−= 1
11  
PnK
nKP
⋅+= 1  
PnK
fbfu ⋅=
1/  
nK*P = fu/fb
Thus, nK = fu/(fb*P) 
     Here, n represents the number of saturable binding sites per mole of protein, P the 
molar concentration of protein binding, K the association constant, and nK the 
contribution constant of nonspecific, non-saturable binding on one site (per molar 
concentration of protein). 
     The association constants for binding were 4.29 × 104 (± 4.2× 103) M-1, 4.41 × 104 
(1.39× 103) M-1 and 1.5 × 106 (2.6 × 105) M-1 for albumin, AAG and SHBG respectively.  
The significance of these binding coefficients are detailed in the ‘Discussion’ section of 
this chapter. 
      
Displacement interactions on binding sites 
     2ME1 concentrations measured in the plasma are 100-200 fold higher than 2ME2 
concentrations after administration of oral 2ME2 123.  Hence, we examined the effect of 
2ME1 on the binding of 2ME2.   There was no change observed in fu of 2ME2 in the 
presence of 2ME1 (10 ng/mL - 10 µg/mL).  (p-value = 0.78, t-test). 
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Pharmacokinetics of unbound 2ME2 
     The equilibrium dialysis method was next applied ex-vivo to define the concentration-
time profiles of total and unbound 2ME2 in 5 patients with cancer that received single 
oral doses of 2ME2.  One patient received 2ME2 at dose of 800 mg, two patients 
received 2ME2 at 1600 mg and two patients received 2ME2 at 2200 mg each.  Total 
2ME2 levels detected in these patients were very low (range: 1.1 ng/mL – 18.6 ng/mL).  
The fu was calculated for all five patients at all the pharmacokinetic time points.  Ex vivo, 
the fu was constant at all the pharmacokinetic time points for all five patients with cancer 
(Figure 54).  The combination of very low/undetectable concentrations of 2ME2 and 
tremendous pharmacokinetic variability in the measured concentrations for 2ME2 
prevents us from presenting a mean plasma concentration-time profile for all five 
patients.    Figure 55 presents a combined concentration-time profile of total and unbound 
2ME2 as measured in one patient who received a single oral dose of 1600 mg 2ME2.  
Table 22 provides a comparison of the pharmacokinetic parameters obtained after 
modeling the bound and total 2ME2 concentrations using WINNONLIN.   
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Figure 54: The mean (symbol) ± SD (error bars) fraction unbound 2ME2 in plasma 
versus time profiles. Data were obtained from five patients with cancer given  
a single oral dose of 2ME2. 
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Figure 55:  Concentration-time profiles of total 2ME2 (ng/mL) and unbound 2ME2 
(ng/mL) in plasma (panel A; ‘▲’ represent unbound 2ME2 concentrations and; ‘■’ 
represent total 2ME2 concentrations; note logarithmic scale on Y axis and points 
connected using straight lines) 
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Table 24: Comparison of 2ME2 bound versus unbound pharmacokinetic 
parameters* 
 
Parameter  Unbound 2ME2       Total 2ME2 
 
Cmax (ng/mL)   0.2                                            18.6  
Tmax (h)   0.5      0.5 
AUC (ng·h/mL)  6.0               704.23 
CL/F (L/h/m2)   213     2272000 
Vd/F (L)   5309     90554210 
T1/2 (h)               17.24     27.63 
R2 of fit   0.99     0.80 
 
* Data were obtained from 1 patient who received 2ME2 orally at a dose of 1600 mg 
Abbreviations: Cmax, peak plasma concentration; Tmax, time to peak concentration; AUC, area under the 
plasma concentration-time curve; CL/F, apparent oral clearance; T1/2, half-life of the terminal phase; Cu, 
unbound drug concentration; Cp, total drug concentration in plasma. 
 
     Thus, from the above data it appears that unbound 2ME2 exhibits a shorter half-life in 
plasma as compared to total 2ME2.  It is premature to make this conclusion based on the 
above data, because of a small sample size.  Further, studies are warranted to determine 
whether plasma protein binding enhances the plasma half-life of 2ME2.   
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Discussion 
     In the present study we have described the in vitro and ex vivo plasma protein binding 
of 2ME2.  The binding of 2ME2 to human plasma was approximately 98 % and 
independent of drug concentration over the clinically relevant range, thus proving right 
the hypothesis #3 of this thesis as listed in chapter 2.  When binding studies were 
extended to individual proteins, it was found that 2ME2 binds extensively to human 
albumin, AAG and SHBG.  The association constant for binding was 4.29 × 104 (± 4.2× 
103) M-1, 4.41 × 104 (1.39× 103) M-1 and 1.5 × 106 (2.6 × 105) M-1 for albumin, AAG and 
SHBG respectively.  Thus, 2ME2 shows low affinity, high capacity type binding to 
albumin and AAG and it shows high affinity, low capacity type binding characteristics 
with SHBG.  It has previously been reported that 2ME2 and 2ME1 bind very strongly to 
SHBG 124.  This strong binding to SHBG has been attributed to the addition of the 
methoxy group at the C-2 position.  The previously reported association constant for 
2ME2 binding to SHBG at 370 C was 15.6 × 108 M-1 125.  The differences between the 
values of our and previously reported association constants of 2ME2 for SHBG binding 
is attributed to the differences in analytical methods, where we utilized direct 
measurement of radiolabeled 2ME2 whereas the previously reported method used 
competitive displacement with testosterone, as well as differences in the source of 
protein.  Both the reported values fall within the range of high affinity binding.  The 
association constant for estradiol to SHBG at 370 C is 0.29 × 109 M-1126.  Thus, 2ME2 
appears to bind less strongly to SHBG than estradiol. The previously reported values for 
the affinity constants of estrone sulfates and ethinyl estradiol for albumin range between 
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1.8 × 104 M-1  to 0.5 × 106 M-1 to 127.  Our reported values for 2ME2 association constant 
for albumin falls within this range previously reported for other steroids.   
     There was a slight but statistically significant increase in the fraction unbound 2ME2 
observed in plasma obtained from healthy volunteers compared to plasma from cancer 
patients. This type of effect of disease state on drug binding has been described 
previously for various agents, including fluconazole 128, methadone 129 and propranolol 
129 due to increase in plasma AAG levels and a concomitant decline in plasma albumin. 
     Although there was very low inter-individual variability in the fraction unbound 
2ME2 in the plasma of cancer patients at the 2ME2 dose levels tested, there was very 
high inter-individual variability in the total 2ME2 concentrations measured. Consistent 
with the in vitro data, almost 98% of drug was bound within the circulation without any 
trend over time.  Although, there was no change in the fraction unbound drug over the 
therapeutically achieved concentrations of 2ME2, there was statistically significant 
difference in fu due to variability in albumin and AAG concentrations in cancer patients.  
But since there was no change in total unbound fraction, a drastic effect of changes in 
protein binding on the pharmacological response to 2ME2 may be unlikely.  The high 
binding to plasma proteins of 2ME2 along with enterohepatic recirculation and the 
metabolic ‘cycling’ of 2ME2 may be a significant contributing factor to its long half life 
in the plasma. 
     In conclusion, a reliable and reproducible equilibrium dialysis method for the 
determination of the fraction unbound 2ME2 in plasma was developed and validated, 
thus achieving objective #4 of this thesis as listed in chapter 2.  The extent of binding of 
2ME2 to albumin and AAG was higher as compared to estradiol, while the extent of 
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binding to SHBG was comparable to estradiol as reported previously 72.  2ME2 was 
found to bind with a high degree of affinity to several human plasma proteins, including 
albumin, AAG and SHBG.  This clearly signifies the importance to account for 
differences in the fraction unbound drug when attempting to extrapolate data obtained in 
in vitro model systems in protein-free media to the clinical situation.   
 
  
 
 
 
CHAPTER SEVEN 
 
Summary and Conclusions 
 
 
 
     This chapter will try to put together all that had been learned in the previous chapters 
and present a complete picture of the clinical pharmacology of 2ME2.  Moreover, we will 
try to explore the reasons for poor bioavailability and low circulating concentrations of 
2ME2 observed after oral dosing even at very high doses.  The major barriers to oral drug 
delivery and systemic exposure are formulation, solubility, permeability, transporter 
effects, first pass metabolism.  We will discuss each of these factors in this chapter.  The 
probable future of drug development of 2ME2 will also be discussed.  
 
Formulation 
     2ME2 was formulated as 200 mg capsules with lactose, sodium starch glycolate, 
colloidal silicon dioxide and magnesium stearate.  The number of capsules ingested by a 
patient as a single dose ranged from two (400 mg q 12 h/DL1) to fifteen (3000 mg q 12 
h/DL5).  Since the number of capsules being ingested is quite high, there has been a 
speculation that the diarrhea resulting in patients on 2ME2 may be because of lactose 
intolerance.  In conjunction, the resulting diarrhea can potentially hamper the absorption 
of the drug.  We had eight episodes of diarrhea (grade 1 or 2) on our clinical trial.  Thus, 
the formulation of 2ME2 as a lactose based capsule was not the most optimal but was not 
likely the most important factor hampering bioavailability. 
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Solubility 
     2ME2 is a poorly soluble compound.  Following table 25 and figure 56 represents the 
solubility profile of 2ME2 from pH 2 to pH 11 130.   
 
 
Table 25: Solubility profile of 2ME2 
 
Buffer pH Solubility (µg/mL)
HCl 2 1.9
Citrate 3 3
Citrate 4 2.8
Citrate 5 3
Phosphate 6 2.3
Phosphate 7 3.3
Phosphate 8 2.8
Borate 9 3.4
Carbonate 10 4.8
Diamine-Glycine 11 46.25  
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Figure 56: Solubility profile of 2ME2 
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     2ME2 possesses poor aqueous solubility spanning the complete pH profile of the 
gastrointestinal tract.  In addition, the solubility of 2ME2 in water is < 0.6 µg/mL 130.  
Thus, 2ME2 when administered along with a 250 mL glass of water will dissolve at the 
most 150 µg of the drug in water 114, not taking the pH into consideration.  Taking the pH 
into consideration the solubility of 2ME2 in 250 mL fluid the amount of 2ME2 dissolved 
will range from 475 µg (pH 1.9) to 700 µg (pH 8).  Thus, 2ME2 can be classified as a 
poorly soluble compound.  Solubility is hence believed to be one of the major factors 
affecting oral bioavailability of 2ME2. 
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Permeability 
     The apparent permeability (Papp) of 2ME2 using  monolayers of intestinal Caco-2 cells 
cultured in Transwell inserts 130, measuring one-way transport from the apical to the 
basolateral side, in comparison with propranolol is depicted in the Table 26 below: 
 
Table 26: Permeability of 2ME2 across Caco-2 cell monolayer 
      
Compound Mean Papp  (X 10-6 cm/s) 
14C-Mannitol 0.89   (0.10) 
3H-Propranolol 13.9  (3.6) 
2ME2 28.8 (4.9) 
      
     Comparing the Papp values of 2ME2 and propranolol, which is a marker for high 
permeability, we can conclude that 2ME2 is a highly permeable drug.  Thus, 2ME2 falls 
within the class 2 compounds in the Biopharmaceutics Classification System (BCS) 114,115 
as defined by the FDA.  A high fraction of 2ME2 that dissolves into gastrointestinal fluid 
will permeate from the apical to the basolateral side and get through to the portal 
circulation.  Permeability of 2ME2 is thus not believed to be a major factor affecting the 
bioavailability. 
 
Transporter Effects 
     Since 2ME2 is a class 2 compound, high permeability will allow ready access into the 
gastrointestinal tract, and thus uptake transporters will have no effect on absorption.  But, 
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the low solubility will limit the concentrations entering the enterocytes, thereby 
preventing the saturation of efflux transporters.  Thus, efflux transporters can potentially 
play a major role in determining the extent of oral bioavailability (Fextent) and the rate of 
absorption.  The effect of efflux transporters needs to be examined in future studies to 
further test this hypothesis.  Although, the efflux transporter effect seems very unlikely 
since there is no increase in the Cmax or AUC with increase in dose as seen in chapter 4. 
 
Food Effects (High-Fat Meals) 
     Food effects result from changes in drug solubility, delay in gastric emptying, 
stimulation of bile flow, change in gastrointestinal pH, increase in splanchnic blood flow 
change in luminal metabolism of drug, and physical or chemical interaction with the 
dosage form 115.  The solubility of 2ME2 will be increased with a high fat meal.  High-fat 
meals are also suspected to inhibit both influx and efflux drug transporters 115.  Since 
uptake transporters are not expected to play a major role in 2ME2 gastrointestinal 
absorption, the inhibition of efflux transporters could potentially increase the extent of 
oral bioavailability (Fextent).    Hence, all the above-mentioned factors combined are 
expected to cause an increase in Fextent.  The time to maximal concentration (tmax) may be 
delayed because of prolonged gastric emptying time.   
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First-pass metabolism 
     First-pass metabolism of a drug starts with the metabolism in the gastrointestinal tract.  
As seen in chapter 5, 2ME2 is highly glucuronidated and is a substrate for CYP 3A 
enzymes, which are present in the gastrointestinal tract.  Due to poor solubility and low 
gastrointestinal concentration of 2ME2, the CYP 3A enzymes and UDP-
glucuronosyltransferases in the gastrointestinal tract will not be saturated and the first 
pass metabolism of 2ME2 will start right from the gastrointestinal tract.  
Sulfonyltransferases are another group of enzymes which are located predominantly in 
the gastrointestinal tract and also play a major role in the metabolism of steroid 
compounds as discussed in chapter 1. But, we were unable to establish sulfation of 2ME2 
in vivo or in vitro.  Thus, we can conclude that 2ME2 arguably undergoes phase I 
metabolism by CYP 3A enzymes and glucuronidation in the gastrointestinal tract.  2ME2 
undergoes extensive metabolism in the liver as seen in chapter 5, glucuronidation being 
the predominant pathway for metabolism.  The predicted in vivo plasma hepatic clearance 
(CLh) of 2ME2 was 862 mL/min, which is more than half the blood flow of the liver.  
This number is believed to be an underestimation of the actual CLh since this calculation 
did not take into consideration the glucuronidation of the phase I metabolites and the 
biliary excretion of the glucuronidated metabolites.  Hence, the actual CLh is believed to 
approach and possibly exceed liver blood flow, thus making 2ME2 a high extraction ratio 
drug.  It can be concluded that first pass effect is also a major player in determining the 
oral bioavailability of 2ME2. 
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Oral Bioavailability Estimates 
     Only about 1% of the total 2ME2 dose administered orally was recovered from the 
urine as glucuronides after 24 hours.  In the preclinical studies of excretion in mice 
(chapter 1), approximately 50% of orally administered [3H]-2ME2 was recovered in the 
urine (~25%) and feces (~25%) combined after 24 hours (one half life, chapter 5).  
Hence, if we assume that an equal amount of 2ME2 is being excreted in feces and urine, 
then we can make a rough estimate of 2ME2 oral bioavailability in humans as being 
about 2%.  This observation is in corroboration with the estimation of 1-2% oral 
bioavailability in mice (chapter 1).   
 
Plasma Protein Binding 
     2ME2 is heavily bound to plasma proteins (approximately 98%), thus decreasing the 
unbound fraction available for the biological activity.  This complements the observation 
that there was no DLT and the MTD was not achieved.  Also, only one patient showed a 
partial response out of twenty that were treated.  The extremely high Vd/F as mentioned 
in chapter 4, is counterintuitive to the observation of extensive plasma protein binding.  
But, the extremely high Vd/F is most probably a reflection of the poor bioavailability of 
the compound and not the distribution characteristics.  2ME2 was found to bind with a 
high degree of affinity to several human plasma proteins, including albumin, AAG and 
SHBG.  The extent of binding of 2ME2 to albumin and AAG was higher as compared to 
estradiol, while the extent of binding to SHBG was comparable to estradiol as reported 
previously 72.  Thus, extensive plasma protein binding is also a major barrier to the 
systemic exposure of 2ME2. 
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Conclusion 
     2ME2 showed exciting preclinical activity in the form of in vitro cell lines studies and 
xenograft studies in terms of biological activity.  But, the solubility and oral 
bioavailability data that were available from the preclinical studies were overlooked, and 
the development of this agent was hurried into the clinic at a premature stage.  
Pharmacokinetic data from previous Phase I clinical trials of 2ME2 should have been 
obtained and studied before embarking upon the clinical trial at NCI with higher doses of 
2ME2.  From an ethical point of view, unfavorable pharmacokinetic results should 
prevent unnecessary exposure of patients to potential harmful and less effective cytotoxic 
drugs.  2ME2 does possess promising antitumor activity as demonstrated by the partial 
response in the ovarian cancer patient (patient #7) and corroborating data from other 
clinical trials, but the low circulating concentrations, tremendous interpatient variability 
and lack of dose proportionality seen in our patients demands a better formulation of 
2ME2 to be developed.  The fact that patient #7 showed had a partial response even in the 
presence of low circulation concentrations of 2ME2, leads us to believe that an active 
metabolite of 2ME2 may be responsible for its biological activity.  Entremed has 
currently developed a new formulation of 2ME2 which is a Nanocrystal Colloidal 
Dispersion (NCD), which achieves significantly higher concentrations as compared to the 
capsular formulation of 2ME2.  However, it still remains to be seen, how much 
improvement in oral bioavailability this approach will achieve.  Another approach that 
could theoretically be tried to improve the bioavailability of 2ME2 is to change the route 
of administration from oral to intravenous. But, this approach would run into problems as 
it would not be a practically feasible option for patients with cancer receiving long term 
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2ME2, since the role of 2ME2 will more than likely be in combination with more 
aggressive therapy to keep the cancer in ‘check’ or in a palliative setting.   
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APPENDIX A 
 
PLASMA CONCENTRATION TIME PROFILES OF 2ME2 IN PATIENTS WITH 
SOLID TUMORS  
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Figure 57: Plasma concentration-time profile of a patient that received a 400 mg 
single oral dose of 2ME2 
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Figure 58: Plasma concentration-time profile of a patient that received a 800 mg 
single oral dose of 2ME2 
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Figure 59: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 60: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 61: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 62: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 63: Plasma concentration-time profile of a patient that received a 1600 mg 
single oral dose of 2ME2 
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Figure 64: Plasma concentration-time profile of a patient that received a 2200 mg 
single oral dose of 2ME2 
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Figure 65: Plasma concentration-time profile of a patient that received a 2200 mg 
single oral dose of 2ME2 
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Figure 66: Plasma concentration-time profile of a patient that received a 2200 mg 
single oral dose of 2ME2 
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Figure 67: Plasma concentration-time profile of a patient that received a 3000 mg 
single oral dose of 2ME2 
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APPENDIX B 
 
LC/MS/MS ANALYSIS OF 2ME2 IN URINE OF PATIENTS WITH SOLID TUMORS 
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Figure 68: Blank human urine after liquid-liquid extraction 
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Figure 69: Calibration standard of 2ME2 spiked in human urine at 5 ng/mL 
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Figure 70: Calibration standard of 2ME2 spiked in human urine at10 ng/mL 
  
 
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00
min0
100
%
MRM of 2 channels,AP+
308.2 > 138.8
4.252e+004
2me_042305_061  Smooth(SG,2x1)  
10 61
2ME-d5
5.45
5701.90
min0
100
%
MRM of 2 channels,AP+
303.1 > 136.8
1.193e+004
2me_042305_061  Smooth(SG,2x1)  
10 61
2ME
5.47
1697.21
 
 
Figure 71: Calibration standard of 2ME2 spiked in human urine at20 ng/mL 
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Figure 72: Calibration standard of 2ME2 spiked in human urine at 2 µg/mL 
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Figure 73: Urine of patient #2 after liquid-liquid extraction 
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Figure 74: Urine of patient #2 after treatment with β-glucuronidase and liquid-
liquid extraction 
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Figure 75: Urine of patient #2 after treatment with sulfatase and liquid-liquid 
extraction 
 
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00
min0
100
%
MRM of 2 channels,AP+
308.2 > 138.8
2.418e+004
2me_042305_047  Smooth(SG,2x1)  
P2S 47
2ME-d5
5.43
3286.27
min0
100
%
MRM of 2 channels,AP+
303.1 > 136.8
1.107e+005
2me_042305_047  Smooth(SG,2x1)  
P2S 47
2ME
5.46
14033.13
2.48
 
 
 
 
 
Figure 76: Urine of patient #3 after liquid-liquid extraction 
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Figure 77: Urine of patient #3 after treatment with β-glucuronidase and liquid-
liquid extraction 
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Figure 78: Urine of patient #3 after treatment with sulfatase and liquid-liquid 
extraction 
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Figure 79: Urine of patient #5 after liquid-liquid extraction 
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Figure 80: Urine of patient #5 after treatment with β-glucuronidase and liquid-
liquid extraction 
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Figure 81: Urine of patient #5 after treatment with sulfatase and liquid-liquid 
extraction 
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Figure 82: Urine of patient #6 after liquid-liquid extraction 
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Figure 83: Urine of patient #6 after treatment with β-glucuronidase and liquid-
liquid extraction 
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Figure 84: Urine of patient #6 after treatment with sulfatase and liquid-liquid 
extraction 
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IN VITRO METABOLISM OF 2ME2 
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Figure 85:  In vitro metabolism of 2ME2 by CYP 1B1 
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Figure 86: Negative control for CYP 1B1 
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Figure 87:  In vitro metabolism of 2ME2 by CYP 2A6 
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Figure 88: Negative control for CYP 2A6 
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Figure 89:  In vitro metabolism of 2ME2 by CYP 2B6 
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Figure 90: Negative control for CYP 2B6 
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Figure 91:  In vitro metabolism of 2ME2 by CYP 2C19 
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Figure 92: Negative control for CYP 2C19 
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Figure 93:  In vitro metabolism of 2ME2 by CYP 2C9 
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Figure 94: Negative control for CYP 2C9 
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Figure 95:  In vitro metabolism of 2ME2 by CYP 2D6 
 
 
 
 
 
 
 
 
CYP 2D6
Time (min)
0 5 10 15 20
m
A
U
0
100
200
300
400
2ME2
 
  
 228
 
Figure 96: Negative control for CYP 2D6 
 
 
 
 
 
 
 
 
 
 
Negative Control for CYP 2D6
Time (min)
0 5 10 15 20
m
A
U
0
100
200
300
400
 
 
 
 
 
 
 
 
  
